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DEVELOPMENT OF CORTICAL GABA CIRCUITRY: IDENTIFYING PERIODS OF 
VULNERABILITY TO SCHIZOPHRENIA 
 
Gil Dov Hoftman, Ph.D. 
University of Pittsburgh, 2013 
 
The development of cognitive functioning is disrupted in many individuals who will later be 
diagnosed with schizophrenia, lagging behind healthy comparison subjects by 1-2 standard 
deviations at clinical onset. Cognitive dysfunction often appears years before clinical onset, is 
the best predictor of functional outcome, and is increasingly recognized as a central feature of 
schizophrenia. The domains of cognitive functioning affected in schizophrenia are mediated, at 
least in part, by prefrontal cortex (PFC) GABA neurons, which show molecular alterations in 
postmortem studies in schizophrenia. One common environmental risk factor for schizophrenia 
is chronic cannabis use, which disrupts cognitive function most prominently during adolescence, 
a time of flux in PFC circuitry that may be a sensitive period for the effects of cannabis use on 
neural circuit maturation. Parvalbumin (PV)-containing GABA neurons may be particularly 
vulnerable to risk factors for schizophrenia since they are altered in the disease, important for 
neural activity associated with cognitive functioning, and have a lengthy period of postnatal 
maturation. However, the nature of PV neuron subtype-specific developmental changes is not 
clear. Therefore, this dissertation focuses on understanding the timing of altered expression 
profiles of GABA-related mRNA levels in schizophrenia, the impact of chronic cannabis 
exposure during adolescence on GABA circuits of the monkey PFC, and the cell type-specific 
nature of postnatal maturation of influential GABAergic connections. Indeed, we find that the 
profile of GABA transmission markers in postmortem PFC tissue in schizophrenia can be 
explained by disrupted development of their mRNA levels; that chronic exposure to the 
psychoactive compound in cannabis during adolescence alters the GABAergic mRNA levels in 
monkey PFC; and that two populations of PV neurons have distinctive modes of maturation in 
monkey PFC.  
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AIS: Axon initial segment 
PV: Parvalbumin 




PVch: Parvalbumin-containing chandelier neuron 
PVb: Parvalbumin-containing basket neuron 
CCKb: Cannabinoid receptor 1-/cholecystokinin-containing basket neuron 
vGAT: Vesicular GABA transporter 
GABA: γ-aminobutyric acid 
GAT1: GABA membrane transporter 1 
GAD67: Glutamic acid decarboxylase, 67 kilodalton isoform 
GAD65: Glutamic acid decarboxylase, 65 kilodalton isoform 
GABAA α1: GABAA receptor subunit α1 
GABAA α2: GABAA receptor subunit α2 
GABAA α4: GABAA receptor subunit α4 
GABAA γ or γ: GABAA receptor subunit γ 




DSI: Depolarization-induced suppression of inhibition 
DSE: Depolarization-induced suppression of excitation 
MOR: µ-opioid receptor  
mGluR1α: Metabotropic glutamate receptor subunit 1α 






Adolescence – the period between childhood and adulthood, which usually coincides with the 
onset of puberty and is behaviorally identified as a period of increased risk seeking and profound 
changes in behavior; The molecular “adolescence” of the prefrontal cortex is defined in this 
dissertation as the period of asymmetric synapse and dendritic spine density reductions that 
occurs between childhood and adulthood, and is independent of puberty status. In macaque 
monkeys, this period of dynamic pruning coincides on average between 15 and 45 months of 
age.  
 
Critical period – a strict time window during which experience provides information that is 
essential for normal development and permanently alters behavior 
 
Development – the extended period from conception to young adulthood when neural circuits 
and behaviors are maturing into their adult form 
 
GABA-related markers – mRNA or proteins of molecules that are either directly involved in 
GABA neurotransmission or are identifiers of GABA neuron subpopulations; In this dissertation, 
GABA-related markers include GAD67, GAD65, GAT1, vGAT, GABAA receptor subunits, PV, 
CR, SST, CB1R, CCK 
 
Neurodegenerative – classic gross pathologically identifiable loss of neurons accompanied by 
gliosis and most frequently associated with Alzheimer’s disease, Huntington’s disease, and 
Parkinson’s disease 
 
PV bouton – overlapping PV-IR and vGAT-IR puncta adjacent to a GABAA receptor γ2-IR 
cluster  
 
Sensitive period – a limited period of development when brain function is highly influenced by 
the effect of experience 
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Working memory – the ability to maintain and manipulate on-line a limited amount of 
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“Portray [people with mental illness] sympathetically, and portray them in all the richness and 
depth of their experience as people, and not as diagnoses.” 
―Elyn Saks
  1 
1.0  GENERAL INTRODUCTION 
1.1 OVERVIEW OF SCHIZOPHRENIA 
1.1.1 Human cost 
Schizophrenia is a neuropsychiatric syndrome that affects roughly 26.3 million people 
worldwide (Global Burden of Disease: 2004 Update, 2008) and is recognized as a leading cause 
of all years lived with severe disability, accounting for 3% of the total years of healthy life lost 
due to disability (Global Burden of Disease: 2004 Update, 2008). Features of schizophrenia 
frequently result in profound suffering, often becoming severe for the first time during late 
adolescence or early adulthood (Lewis and Lieberman, 2000). Schizophrenia also causes 
substantial emotional distress in caregivers, who are often closely related family members 
(Gibbons et al., 1984). The schizophrenia burden also includes persistent financial problems for 
affected persons, caregivers and the community (Gibbons et al., 1984). Direct economic costs 
resulting from schizophrenia include treatment provided in inpatient, outpatient and long-term 
care, as well as criminal justice costs and medication costs (Wu et al., 2005). Indirect costs 
mainly arise from lost productivity suffered by individuals with the illness, their caregivers and 
the community. In the United States in 2002, direct and indirect costs of schizophrenia were 
estimated to be $62.7 billion (Wu et al., 2005). 
A diagnosis of schizophrenia is typically accompanied by significant societal stigma 
(Penn et al., 1994). Many individuals experience decreased life opportunities and a loss of 
independent functioning beyond the impairments of schizophrenia itself, as they are the 
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recipients of harsh stigmatization (Penn et al., 1994). Stigma can involve actual episodes of 
physical, verbal or emotional abuse against an individual with schizophrenia solely because 
he/she has the syndrome (reviewed in Jacoby et al., 2005); and can also be experienced as shame 
due to being “schizophrenic” or fear of encountering discrimination (reviewed in Jacoby et al., 
2005). Although there have been recent efforts to eradicate stigma in schizophrenia, it still occurs 
frequently in this disease and places a substantial burden on affected people (Thornicroft et al., 
2009). 
As a result of the above, a person with schizophrenia is more likely to suffer from 
unemployment, poverty, homelessness, incarceration, recurrent hospitalizations, high rates of 
comorbid medical illness and depression, increased suicide attempts with a suicide completion 
rate of 5-10%, and a reduced life expectancy of 1-3 decades (reviewed in Lewis and Sweet, 
2009; Insel and Scolnick, 2006).  
1.1.2 Epidemiology and clinical features 
Today serious mental illness—mostly schizophrenia—has the same prevalence and disability as 
it did a century ago (Insel, 2010). A recent meta-analysis (McGrath et al., 2008) found that the 
median (10, 90 percent quartiles) estimate per 100,000 people for the lifetime morbid risk was 
720 (310, 2710) and the annual incidence of schizophrenia was 15 (8, 43). Interestingly, men 
have a 40% greater lifetime risk of developing schizophrenia than women (McGrath et al., 
2008). Importantly, the many epidemiological studies examined by meta-analysis have collected 
data over several decades across many countries and diverse cultures, suggesting that on average 
the recorded prevalence and incidence of schizophrenia were similar across time and place. 
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Clinically, schizophrenia is recognized as a constellation of signs and symptoms 
classically grouped into three domains that include positive, negative and cognitive symptoms 
[Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision, (DSM-
IV-TR, 2000)]. Positive symptoms are abnormal behaviors that are present in schizophrenia but 
not in healthy individuals. They include disturbances in perception such as delusions, 
hallucinations and thought disorganization, and are also recognized as the “psychotic” features of 
schizophrenia. Delusions are fixed false beliefs that remain unchanged with a high level of 
conviction in the face of contradictory evidence and are present in roughly 80% of individuals 
with schizophrenia (Andreasen and Flaum, 1991). Hallucinations are internal sensory 
perceptions experienced in the absence of an external stimulus and can occur in any modality. 
Auditory hallucinations are most common in people with schizophrenia, with prevalence 
estimates between 40 to 80% (Andreasen and Flaum, 1991; Thomas et al., 2007). A person 
suffering from schizophrenia usually hears a single or multiple voices that may be 
distinguishable, and often does not recognize whether the voices are being generated internally 
or externally.  
Thought disorganization generally refers to incomprehensible thought patterns or form 
and often appears as loose associations, which are ideas and speech that move off track across 
unrelated topics. Other indicators of thought disorganization can include clang associations in 
which words are used together based on their sounds but not their meaning, as well as 
neologisms, which are invented new words. Disorganized behavior is also common and can 
result a variety of actions including poor maintenance of hygiene, childlike behavior and 
unpredictable agitation. Catatonia, a marked decrease in reactivity to the environment, is an 
extreme manifestation of motor abnormalities in schizophrenia. Some examples of catatonic 
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motor behaviors include reaching an extreme degree of unawareness, maintaining a rigid posture 
and resisting efforts to be moved, and the assumption of inappropriate or bizarre postures ( 
DSM-IV-TR, 2000). 
Negative (or deficit) symptoms represent an absence of typical behaviors, including 
poverty of speech (alogia), lack of initiative (avolition), flattened or inappropriate affect 
(affective dysregulation), inability to experience pleasure (anhedonia), and withdrawal from 
friends and family (asociality). Negative symptoms are often primary symptoms of 
schizophrenia, but sometimes may be influenced by positive symptoms. For example, paranoia 
can lead to asociality, while an unchanging facial expression interpreted as flattened affect may 
result from prolonged medication use (DSM-IV-TR, 2000). 
Cognitive symptoms refer to abnormalities in processes that enable coordinated, 
purposeful thoughts and behaviors (Miller and Cohen, 2001). Cognitive dysfunction occurs 
across a number of domains in schizophrenia, including tests of selective attention, working 
memory, episodic memory, processing speed, and language production and comprehension 
(Elvevag and Goldberg, 2000; Green, 1996; Carter and Barch, 2007). While it is possible that 
people with schizophrenia have specific deficits in multiple cognitive systems, a simpler 
interpretation is that these many deficits reflect a disturbance in cognitive control (reviewed in 
(Lesh et al., 2011). These debilitating symptoms can make a simple conversation or calculation 
difficult to handle and consequently have a profound impact on the individual’s social and 
occupational functioning. Given recent efforts to understand cognitive symptoms in 
schizophrenia, I will review evidence for why they are considered to be core features of the 
illness in the next section. 
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1.1.3 Cognitive dysfunction is central to schizophrenia 
Cognitive deficits are present, quite stable, and persistent in the majority of individuals with 
schizophrenia (Lesh et al., 2011; Elvevag and Goldberg, 2000; Green, 1996). For example, 
individuals at their first episode of schizophrenia already perform, on average, 1-2 standard 
deviations below the mean of comparison subjects (Heaton et al., 2001; Wilk et al., 2004). These 
deficits often appear well before the onset of psychosis and persist independently of psychotic 
relapses (Niendam et al., 2003; Reichenberg et al., 2010) (Figure 1). When cognitive 
dysfunction is defined based on premorbid intellectual functioning and parental education, 98% 
of schizophrenia subjects fall below predicted levels and are thus considered to be impaired 
(Keefe et al., 2005). In genetically identical twins discordant for schizophrenia, the twin 
diagnosed with schizophrenia performed worse than the undiagnosed twin in nearly all cases 
(Goldberg et al., 1990; Goldberg et al., 1995). Cognitive symptoms are also present with milder 
severity but similar form in first-degree relatives (Egan et al., 2001; Sitskoorn et al., 2004). 
Importantly, cognitive impairments best predict an individual’s future employment potential and 
social integration (Addington and Addington, 1999; Lysaker et al., 1995; Harvey et al., 1998; 
Bartels et al., 1997), and a recent meta-analysis found that cognitive function, but not severity of 
positive symptoms, was a significant predictor of employment outcome (Tsang et al., 2010). 
Thus, cognitive deficits are considered to be core features of schizophrenia. 
Although positive symptoms are often most prominent in schizophrenia, they are not 
specific to this syndrome. In fact, no individual symptom results in a certain diagnosis of 
schizophrenia, which is only given once other causes of psychosis are excluded, when the time 
course of psychotic and accompanying negative features is recognized, and with the 
establishment of persistent social and occupational dysfunction (DSM-IV-TR, 2000). Despite 
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being extensively described in the DSM-IV-TR, cognitive features are not currently a formal part 
of the diagnostic criteria for schizophrenia. 
1.1.4 Treatment and outcome 
The treatment of psychosis was revolutionized by the astute but serendipitous discovery of 
antipsychotic medications over a half century ago; however, since then progress in developing 
novel treatments for schizophrenia has been limited (Insel and Scolnick, 2006). Positive 
symptoms are most responsive to, although not completely eliminated by, these antipsychotic 
medications. While effective against positive symptoms, a number of serious adverse events are 
associated with pharmacological treatment including irreversible involuntary movements, 
substantial weight gain, diabetes and hypertension (Fischer and Buchanan, 2011). Critically, 
current antipsychotic medications have little to no effect on negative symptoms (Buchanan et al., 
1998) and cognitive dysfunction in schizophrenia (Goldberg et al., 1993; Harvey and Keefe, 
2001). 
Despite relative success in treating positive symptoms, long-term functional outcomes in 
schizophrenia vary remarkably across individuals depending upon how recovery is defined. For 
example, longitudinal follow-up studies have found that around 40% of patients diagnosed with 
schizophrenia achieve partial social or functional recovery (Crumlish et al., 2009; Lambert et al., 
2008; Menezes et al., 2006), meaning they achieve “an adequate level of social and vocational 
functioning that involves appropriate role functioning, capacity for independent living, and social 
interactions at a regular frequency” (Robinson et al., 2004). However, sustained recovery occurs 
only in about 14% of individuals within the first five years following the initial psychotic 
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episode (Robinson et al., 2004), and an additional 16% experience late phase recovery (Harrison 
et al., 2001).  
Although most people with schizophrenia do not experience sustained recovery, the 
majority of clinical evidence suggests that schizophrenia is not a classic early-onset 
neurodegenerative syndrome similar to the late onset neurodegenerative syndrome described by 
Emil Kraeplin’s colleague, Alois Alzheimer (Zipursky et al., 2012; Andreasen, 2010). For 
example, a recent study found no age by diagnosis interactions on a number of cognitive 
measures in schizophrenia and matched comparison subjects, suggesting that performance on 
cognitive tasks does not decline as a consequence of having schizophrenia (Rajji et al., 2012). 
Instead, most clinical evidence suggests that schizophrenia has a strong neurodevelopmental 
component, with changes in behavior beginning during the premorbid stage (Zipursky et al., 
2012; Andreasen, 2010) (Figure 1). 
Given that many individuals with schizophrenia still have poor functional outcomes that 
are associated with more severe cognitive dysfunction, which in turn is mostly unresponsive to 
current antipsychotic medications, there is a critical need for the development of novel therapies 
that target cognitive dysfunction in schizophrenia. To address this need the National Institute of 
Mental Health has recently formed initiatives that include the Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (Marder and Fenton, 2004) and the Cognitive 
Neuroscience Treatment to Improve Cognition in Schizophrenia (Carter and Barch, 2007). 
1.1.5 Etiology 
The 19th century Germ Theory of Disease postulated that acquired diseases are often caused by 
the presence of a single pathogenic factor that unleashes a complex syndrome (reviewed in 
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Whitcomb, 2012). However, multiple lines of evidence suggest that schizophrenia cannot be 
understood within this framework, since it is increasingly recognized as a complex syndrome 
caused by numerous interacting pathogenic factors that alone are neither necessary nor sufficient 
to cause the syndrome (Bayer et al., 1999; Maynard et al., 2001). Adding to its complexity, 
schizophrenia presents with obvious clinical heterogeneity that may result from diversity, 
different disease entities that exist within a population meeting DSM or International 
Classification of Diseases diagnostic criteria, or from variability, the variance of specific 
components of the disease (reviewed in Lewis and Gonzalez-Burgos, 2008).  
Despite the challenges associated with clinical heterogeneity, a combination of genetic 
and environmental factors appears to be necessary for the expression of schizophrenia (Figure 
1). Evidence from twin, family and adoption studies has shown that the etiology of schizophrenia 
has an appreciable genetic component (reviewed in Cardno and Gottesman, 2000). For example, 
monozygotic “identical” twins share 100% of their genes and have a higher rate of 
schizophrenia, while dizygotic “fraternal” twins share 50% of their genes and have a 
substantially lower rate than monozygotic twins (Gottesman, 1991). However, both monozygotic 
twins are diagnosed with schizophrenia only 40-60% of the time, suggesting that environmental 
factors contribute to the disease pathogenesis (Gottesman, 1991). Taken together with first-
degree sibling (Gottesman, 1991) and adoption studies (Rosenthal et al., 1971), these studies 
have led to high heritability estimates of ~0.7 (reviewed in Cardno and Gottesman, 2000). 
However, there is evidence against simple Mendelian inheritance, as around 60% of individuals 
diagnosed with schizophrenia have neither a first- nor second-degree relative with the illness 
(Gottesman, 1991). Genome wide association studies have shown that as many as 37,000 single 
nucleotide polymorphisms (SNPs) could be contributing to schizophrenia (International 
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Schizophrenia et al., 2009), suggesting that a large accumulation of many risk alleles at many 
loci can result in the schizophrenia syndrome. Rare structural variants, including 22q11 deletions 
and 1:11 chromosomal translocations, have also been strongly associated with schizophrenia 
(Karayiorgou et al., 2010; Millar et al., 2000). In addition, microdeletions or microduplications 
(copy number variants or CNVs) have recently been reported to substantially increase the risk for 
schizophrenia (Stefansson et al., 2008; Guilmatre et al., 2009). Despite these recent exciting 
advances in genotyping methods, the combination of the many genetic susceptibility variants still 
leaves the majority of schizophrenia heritability unexplained. 
A number of studies have found that many environmental factors across prenatal 
development confer risk for schizophrenia (Brown and Derkits, 2010) (Figure 1). For example, 
maternal immune activation due to infection and obstetrical complications are associated with an 
increased risk for schizophrenia (Cannon et al., 2002; Cannon et al., 2001). Moreover, a range of 
postnatal environmental factors like minority group position, childhood trauma, urbanicity and 
cannabis use has consistently been associated with a higher risk of developing schizophrenia 
(van Os et al., 2010). The impact of cannabis use on GABA circuit development is an important 
focus of this dissertation because of its public health implications and biological plausibility in 
schizophrenia.
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Figure 1. Summary of proposed lifetime trajectory of schizophrenia 
(A) The four major stages of illness in schizophrenia. (B) Main groups of subclinical/clinical signs and symptoms at each stage of illness. (C) Key adverse genetic and 
environmental events associated with schizophrenia. (D) Age periods from gestation to senescence. (E) Major neurodevelopmental processes that occur from gestation through 
adolescence and are linked to schizophrenia. (F) Curves show gradual improvement of cognitive control in healthy subjects (solid line) and individuals on course to develop 
schizophrenia (dashed line). The dotted area between the lines represents the growing difference in cognitive control performance from childhood to early after clinical onset. 
Figure based on Lewis and Lieberman 2000 and Insel 2010. 
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1.1.5.1 Cannabis use during adolescence is associated with an increased risk of, and earlier 
onset for, schizophrenia 
Epidemiological studies have consistently found an association between marijuana (cannabis) 
use and higher schizophrenia risk (Moore et al., 2007; Henquet et al., 2005b). Repeated cannabis 
use during adolescence has been associated with an elevated risk for schizophrenia relative to 
usage during adulthood (Arseneault et al., 2002). Cannabis use at age 15 was associated with a 
greater likelihood of being diagnosed with schizophreniform disorder a decade later than was 
cannabis use at age 18 (Fergusson et al., 2003), and has also been associated with an earlier age 
of onset for schizophrenia (Veen et al., 2004; Barnes et al., 2006; Large et al., 2011).  
The consistency and dose-dependent nature of these findings after controlling for a 
number of confounding factors suggest that the effects of cannabis use during early adolescence 
may somehow increase the liability for schizophrenia (Moore et al., 2007; Henquet et al., 
2005b). For example, even after adjustment for factors like age, sex, social class, ethnic group, 
family history of psychiatric illness, city living and use of other drugs, the effect of cannabis on 
schizophrenia risk still persisted though the magnitude of the effect sizes was smaller (Henquet 
et al., 2005b). The concept of reverse causality, which refers to the possibility that people who 
show signs of vulnerability to psychosis are more likely to start using cannabis in order to self-
medicate, has also been examined closely in a number of studies. Most epidemiological studies 
have attempted to rule out reverse causality by excluding at baseline all individuals who ever had 
any psychosis-like experience (Henquet et al., 2005b). In addition, cannabis use by individuals 
with schizophrenia is associated with an increased severity of cognitive impairments and more 
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frequent hospitalization, suggesting that these individuals have increased sensitivity to cannabis 
effects (Grech et al., 2005; D'Souza et al., 2005; Pencer et al., 2005).  
1.1.5.2 Cannabis use is associated with cognitive dysfunction  
Cannabis use is correlated with deficits in cognitive control processes (Kanayama et al., 2004; 
Block et al., 2002). These cognitive impairments continue beyond the period of acute 
intoxication and worsen in a dose-dependent fashion (Solowij et al., 2002). In healthy subjects, 
administration of Δ9-tetrahydrocannabinol (THC), the principal psychoactive molecule in 
cannabis, produces deficits in a variety of cognitive processes including working memory, 
attention and executive control (D'Souza et al., 2004). Also, cannabis use during adolescence is 
associated with more severe cognitive deficits compared to first use later in life (Pope et al., 
2003; Ehrenreich et al., 1999). In addition, individuals who started using cannabis prior to age 17 
had smaller whole brain and cortical gray matter volumes than those who started using cannabis 
later in life (Wilson et al., 2000). 
1.1.5.3 THC is bioactive at cannabinoid receptors that are enriched on cholecystokinin-
containing GABA neurons 
Evidence that the psychoactive effects of THC are mediated by the cannabinoid receptor 1 
(CB1R) emerged from studies in healthy human subjects where the acute psychological effects 
of marijuana and the subjective “high experience” were blocked by pretreatment with a CB1R 
antagonist (Huestis et al., 2001). The two most studied endogenous cannabinoids are lipophilic 
molecules that include anandamide, a partial agonist of CB1R, and 2-arachidonoylglycerol (2-
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AG), a full agonist at CB1R that is present at much higher concentrations in the brain relative to 
anandamide [nanomole vs picomole per gram of tissue] (reviewed in Freund et al., 2003). 
Recent studies in the PFC have shown that CB1R are highly enriched at the presynaptic 
terminals of cholecystokinin-containing basket neurons (CCKb) (Eggan et al., 2010; Marsicano 
and Lutz, 1999). The selective depolarization of a postsynaptic neuron induced a short-term 
depression of GABA release from CB1R-containing terminals innervating that same 
postsynaptic cell (Ohno-Shosaku et al., 2001; Pistis et al., 2002; Wilson and Nicoll, 2001), a 
phenomenon termed depolarization induced suppression of inhibition (DSI) (Figure 2). Another 
phenomenon similar to DSI was found at excitatory synapses (depolarization induced 
suppression of excitation, DSE), suggesting that CB1R can also be localized to glutamatergic 
axon terminals and inhibit the release of glutamate (Kreitzer and Regehr, 2001). 
Cannabinoids that are released from depolarized postsynaptic pyramidal neurons bind to 
presynaptic CB1R on CCKb cells, resulting in a reduction of perisomatic inhibitory input onto 
the same pyramidal cell (Wilson and Nicoll, 2002). Thus, CCKb inputs may contribute to the 
precise firing of PFC pyramidal neurons necessary during working memory tasks. Interestingly, 
THC administration to healthy adult subjects produced especially prominent deficits in the 
manipulation of information in working memory (D'Souza et al., 2004), a feature that strongly 
depends on the PFC and is especially deficient in schizophrenia. These findings suggest that a 
potential shared biological mechanism for the effects of cannabis on cognitive function and the 
increased risk of schizophrenia exists via the alteration of PFC GABA circuitry. 
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Figure 2. The endocannabinoid system and DSI 
In synapse-specific DSI, membrane depolarization of the postsynaptic pyramidal neuron induces the opening of 
voltage-gated calcium channels (1). The influx of calcium leads to an elevation of intracellular calcium (2), which 
triggers the production of the endocannabinoid, 2-AG (3). 2-AG then retrogradely activates the presynaptically 
located CB1R (4), which inhibits the opening of presynaptic terminal N-type voltage-gated calcium channels (5). 
The decline in presynaptic intracellular calcium concentration results in a decreased release of presynaptic GABA-
containing vesicles (6) and a subsequent reduction of terminal-specific GABA neurotransmission. This figure was 
modified from Eggan et al. 2007. 
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1.2 PREFRONTAL CORTEX GABA NEURONS: KEY PLAYERS IN COGNITIVE 
IMPAIRMENT IN SCHIZOPHRENIA AND IN PROTRACTED 
NEURODEVELOPMENT 
1.2.1 Cognitive dysfunction and the prefrontal cortex in schizophrenia 
Cognitive control is dependent upon the coordinated activity of neural circuits that are 
distributed across many brain regions; however, dorsolateral PFC activity appears to be 
responsible for the maintenance of rules for action and response selection (Watanabe, 1992; 
Watanabe, 1990; Asaad et al., 1998). Given the highly connected nature of the dorsolateral PFC 
to other brain regions including motor, sensory and associational areas, the PFC appears to be 
critical hub that integrates extrinsic and intrinsic information for top-down control of behavior 
(reviewed in Miller and Cohen, 2001).  
Working memory, the ability to actively maintain and manipulate information for a short 
period of time in a goal directed fashion, is a prototypical example of a set of cognitive control 
processes that have been studied extensively in humans and non-human primates (Baddeley, 
1992). In schizophrenia subjects, a number of regional cerebral blood flow and functional 
magnetic resonance imaging studies have reported dorsolateral PFC hypoactivity (Minzenberg et 
al., 2009; Glahn et al., 2005; Perlstein et al., 2001; Cannon et al., 2005), yet others have shown 
hyperactivity (Callicott et al., 2000; Manoach et al., 2000; Manoach et al., 1999). Further study 
revealed that healthy individuals demonstrate an “inverted U” shape of dorsolateral PFC 
activation between working memory load and behavioral performance, showing low activation at 
low and high loads, and higher activation at intermediate loads (Callicott et al., 1999). In 
schizophrenia, evidence suggests that this inverted U was left shifted such that these individuals 
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have PFC hyperactivity at lower loads and hypoactivity at moderate loads compared to healthy 
individuals (Callicott et al., 2003; Van Snellenberg et al., 2006). These findings show that 
working memory performance and PFC activity are disrupted in individuals with schizophrenia. 
GABA neurons are critical components of coordinated PFC neural activity during 
working memory performance. Cortical GABA neurons comprise a remarkably diverse group of 
cells that can be categorized based upon distinct electrophysiological, molecular and anatomical 
properties (Ascoli et al., 2008) (Figure 3). Based on their electrophysiological properties, GABA 
neurons can be subdivided into fast-spiking and non-fast-spiking cells (Zaitsev et al., 2009; 
Krimer et al., 2005; Kawaguchi and Kubota, 1993). Fast-spiking neurons can produce action 
potentials at a high frequency with constant interspike intervals, and as a general rule, these cells 
contain parvalbumin (PV), do not contain neuropeptides, and target the perisomatic region 
(soma, proximal dendrites and axon initial segments (AIS)) of pyramidal neurons (reviewed in 
(Armstrong and Soltesz, 2012). PV neurons are estimated to make up ~25% of GABA neurons 
in the primate PFC (Conde et al., 1994), and can be further divided into two major classes: 
basket (PVb) and chandelier (PVch) neurons that target the somata/proximal dendrites and AIS 
of pyramidal neurons, respectively.  
Non-fast-spiking cells are more heterogeneous, including one subpopulation that contains 
the neuropeptide cholecystokinin (CCK), CB1R, no calcium-binding proteins, and also 
innervates pyramidal neuronal somata and proximal dendrites (reviewed in Armstrong and 
Soltesz, 2012). Both PVb and CCKb axons tend to form characteristic terminations onto 
pyramidal cell somata that can look like baskets under light microscopy, while PVch axons form 
distinctive vertical terminal arrays at pyramidal cell AIS called cartridges (Lewis and Lund, 
1990). Two other non-fast-spiking GABA neuron subtypes include the population that contains 
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the calcium-binding protein calbindin, the neuropeptide somatostatin (SST), and mainly 
innervates distal dendrites of pyramidal cells; as well as the group that contains the calcium-
binding protein calretinin (CR), the neuropeptide vasoactive intestinal peptide (VIP) and 
predominantly innervates other GABA neurons. 
Fast synaptic GABA neurotransmission occurs via ionotropic GABAA receptors, which 
are heteropentamers most typically composed of 2α, 2β, and 1γ subunits from 7 different 
families (α1-6, β1-3, γ1-3, δ, ε, θ, ρ1-3) (reviewed in Farrant and Nusser, 2005). Importantly, the 
composition of GABAA receptors can determine their functional properties, since GABAA 
receptors containing α1 subunits (GABAA α1) have much faster decay kinetics than currents 
mediated by GABAA receptors containing other α subunits (Lavoie et al., 1997). In rodent 
hippocampus, postsynaptic GABAA receptor clusters that had a high α1/α2 subunit ratio were 
found to preferentially appose PVb inputs, while clusters that had a lower GABAA α1/α2 ratio 
because of enrichment of GABAA α2 subunits were preferentially adjacent to CCKb inputs to 
pyramidal cell somata/proximal dendrites and to PVch inputs to AIS (Nusser et al., 1996). 
Understanding which GABA neuron subtype(s) are affected in schizophrenia has 
important physiological implications, since different classes target specialized domains of 
pyramidal neurons and presumably affect pyramidal neuron activity uniquely. These GABAergic 
connections appear to be crucial for precisely sculpting neuronal activity both spatially and 
temporally (reviewed in Gonzalez-Burgos and Lewis, 2008). Given the unique morphological 
and molecular profile of GABA neuron subtypes, as well as evidence of their functional 
importance in health and disease, these neurons have become prime candidates for studying 
neural circuit dysfunction in schizophrenia. 
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Figure 3. GABA neuron subtypes in the PFC 
GABA neurons make up a remarkably heterogeneous group of neurons. Different types of GABA neurons target 
different subcompartments of pyramidal neurons (A). Perisomatic targeting terminals arise from CCKb, PVb, and 
PVch neurons (B). Adapted from Hoftman and Lewis 2011. 
1.2.2 Alterations in GABA neurotransmission in schizophrenia 
In schizophrenia, working memory dysfunction may be related to alterations in mRNA and 
protein levels of key regulators of GABA transmission in postmortem PFC tissue. Postmortem 
studies have consistently reported lower mRNA levels of the rate limiting GABA synthesizing 
enzyme, glutamic acid decarboxylase 67 (GAD67) (Akbarian et al., 1995b; Volk et al., 2000; 
Duncan et al., 2010; Curley et al., 2011; Hyde et al., 2011). A recent comprehensive study 
showed that GAD67 protein levels were lower in the PFC of schizophrenia subjects and that 
lower GAD67 protein correlated with lower mRNA levels (Curley et al., 2011). In contrast, 
mRNA levels of a second GABA synthesizing enzyme, glutamic acid decarboxylase 65 
(GAD65), were only slightly reduced or unaltered in the PFC in schizophrenia (Hashimoto et al., 
A B 
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2008a; Hashimoto et al., 2008b; Guidotti et al., 2000). In addition, the density of GAD65-
immunoreactive (IR) puncta was also unchanged (Benes et al., 2000).  
Other markers of GABA transmission are also altered in schizophrenia. Transcript levels 
of the GABA plasma membrane transporter (GAT1), which removes GABA from the synapse, 
were reported lower in a subset of neurons in the PFC of subjects with schizophrenia (Volk et 
al., 2001; Volk et al., 2002). Lower mRNA levels of the postsynaptic GABAA α1 (Akbarian et 
al., 1995a; Hashimoto et al., 2008a; Hashimoto et al., 2008b; Beneyto et al., 2011) but see 
(Duncan et al., 2010), β2 (Beneyto et al., 2011), and γ2 (Akbarian et al., 1995a; Hashimoto et 
al., 2008a), which co-assemble together in the majority of GABAA receptors in the cortex 
(Mohler, 2006), have been found in the PFC in schizophrenia. Interestingly, recent findings 
indicate that GABAA α1 mRNA is lower in pyramidal cells but not GABA neurons in 
schizophrenia (Glausier and Lewis, 2011). However, not all markers of GABA transmission are 
lower in schizophrenia. For example, GABAA α2 mRNA levels are higher in schizophrenia 
(Beneyto et al., 2011), while recent studies reported that mRNA and protein levels of the 
vesicular GABA transporter (vGAT), which loads GABA into presynaptic vesicles at axon 
terminals, were not significantly changed in postmortem PFC tissue from schizophrenia subjects 
(Fung et al., 2011a; Fung et al., 2011b). Some key molecular components of a characteristic 
GABAergic synapse are shown in Figure 4. 
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Figure 4. Synaptic GABA transmission 
Typical GABA presynaptic terminal contains a vast interconnected network of machinery involved in regulating 
neurotransmitter release. Some key components I focus on in this dissertation include (1) the GABA synthesizing 
enzymes, GAD67 and GAD65; (2) the protein that loads GABA into presynaptic terminals, vGAT; (3) Ca2+-binding 
proteins and neuropeptides like PV and CCK; (4) the protein that removes GABA from the synapse, GAT1; and (5) 
postsynaptic GABAA receptors. Adapted from Gonzalez-Burgos et al 2011. 
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1.2.3 Alterations in PV- and CCK-containing GABA neurons in schizophrenia 
Cellular and laminar analyses in the PFC have indicated that the density of neurons with 
detectable levels of GAD67 mRNA was lower by 25-35% across layers 1-5 in subjects with 
schizophrenia (Volk et al., 2000). However, the remaining GABA neurons with detectable levels 
of GAD67 mRNA showed no difference in the mRNA expression levels per neuron. In addition, 
the density of neurons expressing GAT1 mRNA was lower by 21-33% across layers 1-5 in 
schizophrenia and the expression level of GAT1 mRNA per neuron did not differ across subject 
groups (Volk et al., 2001). Since the total number of PFC neurons in schizophrenia appears to be 
unchanged (Akbarian et al., 1995b; Thune et al., 2001), these findings suggest that markers of 
GABA transmission are impaired in a subset of GABA neurons of the PFC in schizophrenia. 
In the PFC of schizophrenia subjects, ~50% of PV mRNA-positive neurons were 
reported to have undetectable levels of GAD67 mRNA in a dual label in situ hybridization study 
(Hashimoto et al., 2003). PV expression was also lower in schizophrenia subjects, and this 
difference occurred in layers 3 and 4, where lower GAD67 mRNA levels were also reported in 
the same subjects. However, neither the density of neurons with detectable levels of PV mRNA 
nor the density of PV-IR neurons differed between groups. In addition, PV and GAD67 mRNA 
were lower within the same cells in subjects with schizophrenia (Hashimoto et al., 2003). These 
findings suggest that GAD67 mRNA levels are reduced in PV-containing neurons that have 
lower, but still detectable, levels of PV mRNA. Markers of PVch inputs to pyramidal cell AIS 
are also affected in schizophrenia. For example, the density of cartridges detectable by GAT1-IR 
was 40% lower in schizophrenia (Pierri et al., 1999; Woo et al., 1998). The density of 
postsynaptic GABAA α2 immunoreactivity was higher by more than 100% in the illness (Volk et 
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al., 2002) and ankyrin-G (AnkG)-IR structures, a structural protein that is concentrated at AIS 
and nodes of Ranvier, was lower by 19% in the illness (Cruz et al., 2009b).  
Lower levels of GAD67 mRNA in the PFC are not exclusive to PV neurons in 
schizophrenia, since they were also reported in layers 2 and 5, where PV mRNA expression was 
unchanged (Hashimoto et al., 2003). One class of GABA neurons whose somata are located 
outside of layers 3 and 4, and thus may account for lower GAD67 mRNA is the CCKb. CB1R 
mRNA and protein levels, as well as those for CCK, are also lower in schizophrenia (Eggan et 
al., 2008; Hashimoto et al., 2008a), and changes in GAD67, CB1R and CCK mRNA were 
significantly correlated in the same subject pairs (Eggan et al., 2008). Finally, not all PFC 
GABA neurons appear to be affected in schizophrenia since CR-containing neurons, the largest 
population of PFC GABA neurons in this region (Conde et al., 1994), did not show alterations in 
CR or GAD67 mRNA levels (Hashimoto et al., 2003). Taken together, these findings suggest 
that the GABA neuron subtypes affected in schizophrenia include both PV- and CCK-containing 
neurons (Figure 5).  
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Figure 5. Changes in perisomatic GABA neurotransmission in schizophrenia 
CCKb neurons have lower levels of CCK mRNA and CB1R mRNA and immunoreactivity (purple), PVb neurons 
have lower PV mRNA levels and GAD67 protein in their terminals (magenta), and PVch have lower GAT1-
immunoreactivity in their axons (green) in the PFC from subjects with schizophrenia. The density of GABAA α1-IR 
receptor clusters is lower, and of GABAA α2-containing receptors at the AIS is higher, in schizophrenia (white ovals 
on blue pyramidal (P) cell). 
1.2.4 PFC circuitry and cognitive control continue to develop during adolescence in 
monkeys and humans 
In humans and monkeys, PFC circuitry and working memory performance continue to mature 
through adolescence (Luna et al., 2004; Sowell et al., 1999; Giedd et al., 1999). In humans, adult 
levels of working memory performance are not reached until around age 20, an improvement 
that is associated with increased levels of PFC activity (Luna et al., 2004). In line with these 
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findings, substantial changes in brain function occur during adolescence in parallel with an 
anatomical decrease in frontal cortical synaptic density. 
As in humans, monkeys also continue to improve in working memory performance as 
they age through adolescence. In rhesus monkeys, the ability to perform working memory tasks 
first appears between 2-4 months of age and progressively improves to reach adult levels of 
performance after 3 years of age (Goldman-Rakic, 1987). This improvement in working memory 
performance appears to depend increasingly on PFC activity, since reversible cooling of PFC 
does not impair working memory performance in monkeys 9-16 months of age, produces modest 
impairment in animals between 19-31 months of age, and substantially impairs performance in 
animals over 3 years of age (Alexander, 1982; Alexander and Goldman, 1978). In 
electrophysiology studies some PFC neurons have increased firing during the delay period of 
working memory tasks, and the loss of this delay activity is associated with errors in 
performance. Between 1-3 years of age, there is a doubling in the amount of PFC neurons 
exhibiting delay-related activity (Goldman-Rakic, 1987).  
Since opportunities to directly study the normative postnatal refinements in PFC circuitry 
at the cellular level in humans are limited, rhesus macaque monkeys provide an excellent model 
developmental system. Relative to rodents, macaque monkeys have an expanded PFC that 
develops over a long time period much like the human PFC (Nelson and Winslow, 2009). 
Primates and rodents also show developmental differences in the location of origin (Letinic and 
Rakic, 2001; Xu et al., 2004), physiological properties (Povysheva et al., 2007; Povysheva et al., 
2008) and proportions of GABA neuron subtypes (Gabbott and Bacon, 1996; Gabbott et al., 
1997) in the PFC.  
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The postnatal developmental trajectory of excitatory synapse density, which exhibits four 
distinct phases in both macaque and human PFC, has been best characterized using electron 
microscopy techniques (Bourgeois et al., 1994; Huttenlocher, 1979; Petanjek et al., 2011). In 
monkey PFC, the early postnatal period, between birth and ~3 months, includes a rapid increase 
in excitatory synaptic density; a relatively quiescent childhood period follows, between ~3 and 
15 months, when the density of excitatory synapses is at a plateau; the adolescence period then 
lasts between ~15 to 45 months, including the period of excitatory synapse pruning; and the adult 
stage is reached when the density of excitatory synapses stabilizes. Although inhibitory synaptic 
density appears to be unchanged during adolescence in monkey PFC (Bourgeois et al., 1994), 
dynamic changes in the expression of regulators of GABA transmission have still clearly been 
observed (Cruz et al., 2009a; Cruz et al., 2003; Erickson and Lewis, 2002). Late developmental 
refinements in dendritic spine densities and GABA transmission markers occur in parallel within 
the same cortical layers (Anderson et al., 1995). While the term adolescence can be defined in 
many different ways, for the purposes of this dissertation adolescence is defined as the period of 
excitatory synaptic pruning in the PFC, which lasts between 15 and 45 months in monkeys and 
around 12-20 years in humans.   
In monkey PFC, immunoreactivity of presynaptic cartridge markers and pyramidal cell 
AIS markers follow complex and protracted postnatal trajectories that coincide with the 
excitatory synaptic developmental changes (Figure 6). For example, detectability of PV-IR 
cartridge density increases from around birth to 3 months of age, plateaus until around 18 months 
of age, and substantially declines during adolescence to reach adult levels (Cruz et al., 2003). In 
contrast the density of puncta detectable by PV immunoreactivity progressively increases 
through adolescence to reach adult levels (Erickson and Lewis, 2002). Since the number of 
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synapses per AIS across pyramidal neurons ranges from 0 to >20 (DeFelipe and Farinas, 1992; 
DeFelipe et al., 1985) and the proportion of AIS with detectable cartridges differs by cortical 
layer, age and label used to identify PVch terminals, only a small subset of pyramidal neurons 
has a visible cartridge associated with AIS. As a result, a plausible interpretation of the PV 
immunoreactivity studies is that the number of cartridges or cartridge terminals may decrease 
and the number of PV-IR puncta may increase during postnatal development. While the extended 
maturation of PV-IR puncta and cartridges is necessary for establishing adult circuits, it may also 
provide a window for both genetic and environmental factors to perturb these changing circuits. 
In contrast, CCK-IR profiles reach adult levels of stability before puberty onset in monkey PFC 
(Oeth and Lewis, 1993). Therefore, manipulation of CCKb inputs during adolescence may have 
unique developmental consequences for PVb and PVch neurons that are still in flux.  
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Figure 6. Developmental trajectories of PFC neural circuits and timing of risk factors for schizophrenia 
(A) Excitatory synaptic number changes and maturation continue through adolescence in monkey PFC. (B) Markers 
of perisomatic GABAergic neurotransmission have complex and protracted postnatal developmental trajectories in 
monkey PFC. (C) Genetic and environmental risk factors for schizophrenia occur from conception through late 
adolescence/young adulthood in human PFC, across equivalent periods of primate PFC maturation. Reproduced 
from Hoftman and Lewis 2011. 
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1.2.5 Evidence for a sensitive period of development: The effects of cannabis on PFC 
circuitry during adolescence 
Adolescence represents a period of dynamic change in brain structure and function (Casey et al., 
2010). In humans, neuroimaging studies have revealed that frontal lobe cortical gray matter 
volume decreases while white matter shows a volumetric increase (Sowell et al., 2004; Sowell et 
al., 2002). These late changes, along with a postmortem structural developmental refinements in 
human and monkey PFC (1.2.4), coincide with the ability to perform better on cognitive tasks 
such as working memory. 
Since PV neurons undergo substantial refinement in parallel with improvements in 
working memory function during adolescence, and GABA release from CCKb inputs that target 
PV neurons (Karson et al., 2009) is suppressed by CB1R activation; adolescence may represent 
a sensitive period for the effects of cannabis exposure. By indiscriminately suppressing GABA 
release from CCKb neurons, THC is poised to alter the activity of glutamatergic and GABAergic 
inputs to PV neurons. The resulting alterations in the regulation of PV neurons by pyramidal 
neuron axon collaterals may perturb the developmental refinements that normally occur during 
adolescence. The THC-mediated suppression of GABA release from perisomatic CCKb inputs 
may also affect perisomatic PV neuronal inputs to pyramidal neurons directly. In turn, these 
events could produce alterations in circuit mechanisms that are required for the maturation of 
working memory. These ideas will be tested in 3.0. 
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1.3 GOALS OF THIS DISSERTATION 
Given the large number of risk associations in schizophrenia, it is imperative not only to focus on 
the disease and attempt to treat the pathophysiology, but also to focus on health and preempting 
symptom expression. The classic disease model posits that the etiology “unleashes pathogenic 
processes that give rise to a pathological entity. This pathological entity perturbs normal 
physiology to produce the illness pathophysiology, which disturbs the milieu in a way that 
results in the emergence of the clinical syndrome” (Lewis et al., 2005). Thus, interpreting 
neuropathological findings in schizophrenia requires knowing whether they represent an 
upstream cause of the illness, a consequence of pathogenic processes, a compensation for the 
pathophysiology induced by the pathological entity, or a confound of the illness (Lewis and 
Gonzalez-Burgos, 2008). Understanding their potential contribution to disease pathogenesis 
requires studying the normal developmental trajectories of vulnerable neural circuits. Therefore, 
the normal maturation of neural circuits that subserve working memory function is the focus of 
the particular proposal, since abnormalities in these neural circuits are thought to underlie core 
cognitive disturbances in schizophrenia. 
In the PFC during postnatal development, substantial changes occur in the expression of 
mRNA and protein for key functional components of GABA neurotransmission that are 
implicated in schizophrenia pathology. Therefore, the purpose of this dissertation is to determine 
the timing of GABA neuron changes in the PFC (2.0), the impact of an environmental risk factor 
on adolescent GABA neuron maturation (3.0), and the cell type-specific nature of developmental 
changes in perisomatic targeting GABA terminals (4.0). This dissertation aims to address this 
purpose by asking the following questions: 1) Can altered PFC expression of GABA-related 
genes in schizophrenia be explained by disturbances in their developmental mRNA expression 
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trajectories (2.0)?; 2) What are the consequences of chronic THC exposure during adolescence 
on PFC GABA circuitry (3.0)?; and 3) What is the postnatal developmental profile of two PV-
containing axon terminal populations that target pyramidal neurons in the monkey PFC (4.0)? 
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2.0  ALTERED CORTICAL EXPRESSION OF GABA-RELATED GENES IN 
SCHIZOPHRENIA: EVIDENCE FOR DISRUPTED DEVELOPMENTAL 
TRAJECTORIES 
Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA. Altered cortical expression 
of GABA-related genes in schizophrenia: Evidence for disrupted developmental trajectories. In 
preparation. 
2.1 INTRODUCTION 
Deficits in certain cognitive processes, such as working memory, are common in individuals 
with schizophrenia and have been attributed to dysfunction of the PFC (Barch and Ceaser, 2012). 
This dysfunction appears to reflect, at least in part, alterations in molecular markers of GABA 
neurotransmission (Benes and Berretta, 2001; Lewis et al., 2005; Mirnics et al., 2000). For 
example, multiple postmortem studies of schizophrenia subjects have documented lower mRNA 
levels for the principal enzyme responsible for cortical GABA synthesis, GAD67 (Akbarian et 
al., 1995b; Volk et al., 2000; Guidotti et al., 2000; Duncan et al., 2010; Hyde et al., 2011; 
Vawter et al., 2002; Straub et al., 2007). Although less well-studied, mRNA levels of the 
presynaptic GAT1, which is responsible for the reuptake of extracellular GABA, have also been 
reported to be lower (Volk et al., 2001), whereas mRNA levels of vGAT, which loads GABA 
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into presynaptic vesicles, have been reported to be unchanged (Fung et al., 2011b) in the PFC of 
schizophrenia subjects. On the postsynaptic side, mRNA levels of two of the most common 
GABA ionotropic receptor subunits, GABAA α1 and GABAA α2, appear to be lower and higher, 
respectively, in some (Akbarian et al., 1995a; Beneyto et al., 2011; Volk et al., 2002) but not all 
(Duncan et al., 2010) studies of schizophrenia. 
These alterations may be more common in particular subsets of cortical GABA neurons. 
For example, mRNA levels of the calcium-binding protein PV, which is expressed in a subset of 
GABA neurons, are lower in the PFC in schizophrenia (Mellios et al., 2009; Fung et al., 2010; 
Hashimoto et al., 2003; Volk et al., 2012a) and PV-containing neurons also exhibit lower 
expression of GAD67 mRNA (Hashimoto et al., 2003) and contain lower levels of GAD67 
protein in their axon terminals (Curley et al., 2011). Importantly, these differences appear to 
reflect disease-related reductions in gene expression and not a deficit in the number of PV-
containing neurons (Akbarian et al., 1995b; Hashimoto et al., 2003). In addition, mRNA levels 
of the neuropeptide SST, which is expressed in a separate subpopulation of GABA neurons, have 
also consistently been reported to be lower in the PFC of subjects with schizophrenia (Morris et 
al., 2008; Mellios et al., 2009; Fung et al., 2010; Volk et al., 2012a; Hashimoto et al., 2008a). In 
contrast, mRNA levels for the calcium-binding protein CR, which is expressed in >40% of PFC 
GABA neurons that contain neither PV nor SST, are not lower in the PFC of individuals with 
schizophrenia (Hashimoto et al., 2008a; Fung et al., 2010; Hashimoto et al., 2003; Volk et al., 
2012a). 
Understanding the potential contributions of alterations in markers of GABA 
neurotransmission to working memory impairments in schizophrenia requires knowledge of 
whether they represent causes, consequences or confounds of the underlying disease process 
  33 
(Lewis and Gonzalez-Burgos, 2008). The reported findings do not appear to be confounds due to 
either a non-specific down-regulation or general degradation of cortical mRNAs, since different 
GABA-related transcripts are lower, higher or unchanged in the illness (Duncan et al., 2010; 
Fung et al., 2010; Hashimoto et al., 2008a; Hashimoto et al., 2003; Benes and Berretta, 2001; 
Volk et al., 2002). Other findings suggest that the observed transcript alterations are not 
attributable to confounding factors such as medications, substance use or other comorbid factors 
(Volk et al., 2002; Curley et al., 2011; Morris et al., 2008; Hashimoto et al., 2003). 
Given that altered levels of GABA-related transcripts were observed in postmortem 
studies of schizophrenia subjects with varying illness duration, they could reflect the 
consequences of being chronically ill. If so, then the magnitude of the GABA-related transcript 
alterations would be expected to co-vary with illness duration. Alternatively, these alterations 
could be part of a causal developmental pathway leading to PFC dysfunction and working 
memory impairments in schizophrenia. For example, working memory performance and the 
associated activation of the PFC undergo a protracted maturation with adult levels of 
performance not achieved until late adolescence (Luna et al., 2004). Interestingly, a recent 
longitudinal prospective cohort study reported that in individuals who were later diagnosed with 
schizophrenia working memory function did not differ from comparison subjects at age 7, but 
then failed to improve with age at the normal rate (Reichenberg et al., 2010). Thus, disturbances 
in the developmental trajectories of GABA-related transcripts that occurred prior to the clinical 
onset of schizophrenia could be causal factors contributing to working memory impairments in 
the illness (Hoftman and Lewis, 2011). 
In order to discriminate between the “chronic illness consequence” versus 
“developmental cause” explanations of altered GABA-related gene expression in schizophrenia, 
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we undertook two studies. First, we quantified levels of transcripts that either mediate GABA 
neurotransmission or are selectively expressed in specific subpopulations of cortical GABA 
neurons in the PFC from 42 matched pairs of schizophrenia and comparison subjects, and 
evaluated these data as a function of illness duration. Second, because it is not possible to assess 
the developmental trajectories of GABA-related transcripts in subjects with schizophrenia, we 
quantified the expression of these same transcripts in the PFC from 49 rhesus monkeys ranging 
in age from one week postnatal to adulthood. We then compared the developmental trajectory of 
each transcript with its expression status in schizophrenia to determine if a disturbance during 
development could account for the pattern of GABA-related transcript alterations seen in the 
illness. 
2.2 METHODS 
2.2.1 Human Studies 
Brain specimens (n=84) were obtained during routine autopsies conducted at the Allegheny 
County Medical Examiner’s Office (Pittsburgh, PA) after consent was obtained from the next-of-
kin. Consensus DSM-IV-TR diagnoses for each subject were made using structured interviews 
with family members and review of medical records (Volk et al., 2012a); the absence of a 
psychiatric diagnosis was confirmed in healthy comparison subjects using the same approach. To 
control for experimental variance, subjects with schizophrenia or schizoaffective disorder (n=42) 
were matched individually to one healthy comparison subject for gender, and as closely as 
possible for age, and samples from both subjects in a pair were processed together throughout all 
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stages of the study. The mean age, postmortem interval (PMI), brain pH, RNA integrity number 
(RIN) (Agilent Bioanalyzer, Walbronn, Germany), and tissue storage time (TST) did not differ 
between subject groups (Table 1; Appendix A1, Table 6). The University of Pittsburgh’s 
Committee for the Oversight of Research Involving the Dead and Institutional Review Board for 
Biomedical Research approved all procedures. 
 
    Table 1. Summary of demographic and postmortem characteristics of human subjects 
 
Frozen tissue blocks from each subject were confirmed to contain PFC area 9 using 
Nissl-stained tissue sections cut on a cryostat at 40 μm thickness (Volk et al., 2000). Gray matter 
from adjacent sections was separately collected into a tube containing TRIzol reagent using a 
method that ensured minimal white matter contamination and excellent RNA preservation (Volk 
et al., 2012a). 
Levels of vGAT, GAT1, and GABAA α1 mRNAs were quantified by real-time 
quantitative PCR (qPCR) using previously described methods (Volk et al., 2012a). The results of 
similar studies for GAD67, PV, CR, and SST mRNAs in the same cohort of subjects have been 
previously reported (Volk et al., 2012a; Curley et al., 2011). Briefly, qPCR was performed using 
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Power SYBR Green fluorescence and the StepOnePlus Real-Time PCR system (Applied 
Biosystems). Based on their stable relative expression levels between schizophrenia and 
comparison subjects (Hashimoto et al., 2008a), three reference genes (β-actin, cyclophilin-A, 
and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) were used to normalize the target 
gene expression levels. The amplification efficiency for each primer pair across a range of cDNA 
dilutions was greater than 96% for each of the target and reference genes, and dissociation curve 
analyses confirmed a single and specific amplification product. cDNA samples from both 
subjects in each pair were processed together in quadruplicate on the same PCR plate. The mean 
coefficient of variance (SD) of the replicate measures was less than 0.04 (0.02) for all transcripts. 
The delta CT (dCT) for each target transcript was calculated by subtracting the geometric mean 
of the reference genes from the CT of the target transcript. Since this dCT represents the log2-
transformed expression ratio of each target transcript to the geometric mean of the reference 
genes, the relative expression level of the target transcript was calculated as 2-dCt (Vandesompele 
et al., 2002). 
2.2.2 Monkey Studies 
Forty-nine rhesus monkeys (Macaca mulatta) ranging in age from postnatal 1 week to 11.5 years 
were used. Animals were housed according to age as previously described (Erickson and Lewis, 
2002). All housing and experimental procedures were conducted in accordance with the 
guidelines of the USDA and the NIH Guide for the Care of Animals, and with approval from the 
University of Pittsburgh’s IACUC. 
Twenty-one animals were perfused transcardially with ice-cold modified artificial 
cerebrospinal fluid following deep anesthesia induced with ketamine and pentobarbital; in 5 of 
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these animals, a small tissue block from the left principal sulcus had been surgically excised for 
in vitro electrophysiology studies 2-4 weeks prior to perfusion (Table 2; Appendix A2, Table 
7). The remaining 28 animals were experimentally naïve. After deep anesthesia with ketamine 
and pentobarbital was induced, the brains were removed. For all animals, the right hemisphere of 
each brain was blocked coronally and each block was frozen and stored at -80oC. 
Table 2. Summary of rhesus monkeys used in this study 
 
 
Frontal pole sections (40 µm) composed entirely of gray matter were collected into tubes 
containing TRIzol reagent in a manner that ensured excellent RNA preservation (Hashimoto et 
al., 2008b). Area 10 was used due to the availability of tissue from that cortical region for each 
animal. qPCR was conducted as described for the human study with the following differences. 
Primer sets were designed against the macaque sequences of the same seven target genes used in 
the human studies, as well as two reference genes, β-actin and cyclophilin-A, which exhibited 
stable relative expression levels across the postnatal developmental ages studied (F7,41=1.594 
p=0.164 in the present study, and as previously reported (Volk et al., 2012b)). GAPDH was not 
used as a reference gene since its mRNA levels appeared to be unstable across early postnatal 
development (Volk et al., 2012b). 
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2.2.3 Statistical Analyses 
Two ANCOVA models were used to examine the effect of diagnosis on vGAT, GABAA α1 and 
GAT1 mRNA levels. The unpaired ANCOVA model included mRNA level as the dependent 
variable, diagnostic group as the main effect, and any relevant covariates that were significantly 
related to mRNA level. Since subjects were also paired to account for the parallel processing of 
tissue samples from a pair and to balance diagnostic groups for sex and age, a second paired 
ANCOVA model including subject pair as a blocking factor was also employed. Both models 
produced similar results for all transcripts, and results from the unpaired ANCOVA model are 
reported. There were no subject outliers and the differences in the reported degrees of freedom 
represent differences in the number of covariates used in a given analysis. 
To explore whether the alterations in GABA-related transcript levels in schizophrenia 
subjects were a consequence of the disease process, the correlations between illness duration (the 
difference between a schizophrenia subject’s age at death and age at clinical onset) and the age-
adjusted percent difference (within-pair schizophrenia subject minus comparison subject) in 
expression of each mRNA transcript were computed. In addition, the age by diagnosis 
interactions were assessed using the unpaired ANCOVA model. If the age by diagnosis 
interaction was not significant, then the age effect was considered to be the same for both subject 
groups. If the age by diagnosis interaction was significant, the effects of age across the lifespan 
were examined using regression models to obtain computational estimates of age effects on 
GABA-related transcript expression before and after illness onset in the schizophrenia subjects. 
For the schizophrenia subjects, these models included the age at clinical onset, the illness 
duration, and relevant covariates, whereas for the comparison subjects the age effect was 
predicted to be constant over time. The model for schizophrenia subjects predicted the intercept 
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and slopes of the age effect before and after clinical onset where mRNA expression level at the 
age at death for schizophrenia subjects equaled the sum of the intercept β0s (i.e., transcript level 
at birth) and β1s*age at clinical onset and β2s*illness duration terms. The model for comparison 
subjects predicted the intercept and slope of the overall age effect, and mRNA levels for these 
subjects at death equaled the sum of the intercept β0c and βc*age at death (Appendix B, Figure 
22). Hypothesis testing was conducted to determine whether the rate of transcript level decline 




The relationship of the within-subject pair differences for transcript levels to each of the 
following potential confounds were examined by two sample t-tests: gender, diagnosis of 
schizoaffective disorder, death by suicide, substance use diagnosis at time of death, or 
antidepressant, antipsychotic, or benzodiazepine use at time of death. Medication use at time of 
death was determined from the results of toxicology testing and and/or records of prescriptions 
active at the time of death. Subjects with a documented history of medication non-adherence and 
negative toxicology screen were assumed to not be taking medications at time of death. 
All analyses were implemented in SAS PROC GLM (Version 9.2, SAS Institute, Inc., 
Cary, NC), and all tests were conducted at 0.05 level. 
For the monkey studies, the correlations between age and each mRNA level were 
determined using Pearson’s correlation coefficient. A second analysis used an ANCOVA model 
in which animals were placed into one of four age groups based on existing data regarding 
probable inflection points in the maturation of primate PFC circuitry. Such inflection points have 
been best studied for the postnatal development trajectory of excitatory synapse density, which 
exhibits four distinct phases in both macaque and human PFC (Bourgeois et al., 1994; 
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Huttenlocher, 1979; Petanjek et al., 2011). Therefore, each animal in the present study was 
assigned to one of the following four age groups: 1) perinatal, 0.25-1 mo of age, within the 
period of a rapid increase in excitatory synaptic density; 2) childhood, 3-9 mo, within the period 
when the density of excitatory synapses is at a plateau; 3) adolescence, 15-37 mo, within the 
period of excitatory synapse pruning; and 4) adult, 42-138 mo, during the period when the 
density of excitatory synapses is at stable adult levels. Thus, for the purposes of this manuscript, 
a developmental trajectory refers to the pattern of change in the level of a transcript over 
postnatal development from 1 week of age to mid-life, the approximate age range of the 
available monkey cohort. The ANCOVA model for gene expression used age group as a factor 
and TST as a covariate. Tukey tests with α=0.05 were conducted for post hoc comparisons 
between age groups. 
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2.3 RESULTS 
2.3.1 GABA-related transcript expression in schizophrenia 
In PFC area 9, levels of vGAT (-7%, F1,78=4.13, p=0.046) and GABAA α1 mRNAs (-6%, 
F1,78=8.29, p<0.01) were significantly lower in the subjects with schizophrenia, but GAT1 
mRNA levels did not differ (F1,78=0.39, p=0.53) between groups (Figure 7A-C). We found that 
vGAT (F1,78=5.96, p=0.02) and GAT1 (F1,78=5.72, p=0.02) mRNA levels were negatively 
associated with TST. No other covariates were related to mRNA levels or significantly differed 
between diagnostic groups (Table 1), and thus were not included in the reported statistical 
models. Some of these subject pairs were included in previous studies of GABAA α1 and GAT1 
mRNA levels (Volk et al., 2001; Beneyto et al., 2011) using in situ hybridization (Appendix A1, 
Table 6). In the newly studied schizophrenia subject cohort (n=19 pairs) alone, GABAA α1 
mRNA levels were still significantly lower (-4.4%, F1,32=5.38; p=0.03), and GAT1 mRNA 
expression still did not differ in schizophrenia subjects (F1,32=0.04; p=0.85) from comparison 
subjects. Levels of vGAT, GABAA α1 and GAT1 mRNAs did not differ as a function of gender, 
diagnosis of schizoaffective disorder, death by suicide, substance use diagnosis at time of death, 
or antidepressant, antipsychotic, or benzodiazepine use at time of death (all |t|<1.96, p>0.05). In 
this same cohort of 42 subject pairs using the same qPCR method, mRNA levels for GAD67, 
PV, and SST were lower, and mRNA levels for CR were higher, in the subjects with 
schizophrenia (Curley et al., 2011; Volk et al., 2012a). 
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Figure 7. GABA-related mRNA levels in PFC from schizophrenia and comparison subjects.  
vGAT (A), GABRA1 (B), and GAT1 (C) mRNA levels in PFC from schizophrenia and comparison subjects. Scatter plots show the transcript levels for each 
matched pair of a comparison and either a schizophrenia (circles) or schizoaffective disorder subject (triangles). X- and Y-axes indicate the transcript expression 
ratio (2-dCT) for the comparison and schizophrenia (or schizoaffective) matched subject pairs. Pairs below the dashed unity line have lower transcript levels in the 
schizophrenia (or schizoaffective) subject relative to the comparison subject. 
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We next determined whether levels of GABA-related transcripts altered in schizophrenia 
were correlated with illness duration. The age-adjusted, within-pair, percent difference in 
transcript expression was plotted against illness duration for each schizophrenia subject. The 
age-adjusted percent differences of the expression levels of all transcripts—GAT1 excluded 
since it did not differ between schizophrenia and comparison subjects—did not significantly 
correlate with illness duration (all |r|< 0.270; p>0.08) (Figure 8). In addition, the age-adjusted 
percent differences of the expression levels for these same transcripts did not significantly 
correlate with age at illness onset (all |r|< 0.250; p>0.12). 
We further examined if any GABA-related transcripts altered in schizophrenia exhibited 
an age-related effect that differed between diagnostic groups. There was no significant age by 
diagnosis interaction on mRNA levels for all GABA-related markers studied (all F1,77<1.60, 
p>0.21), with the exception of GAD67 (F1,77=4.27; p=0.04) (Figure 9). 
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Figure 8. Within-pair percent difference (schizophrenia - comparison subject) in PFC transcript levels versus 
illness duration in schizophrenia subjects.  
Pearson’s correlation coefficient (r) was not statistically significant for any of the GABA-related mRNA levels 
examined that were altered in schizophrenia (A-F). For each panel, each matched pair of schizophrenia and 
comparison subjects is shown as an open black circle. 
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Figure 9. Interaction of age by diagnosis on GABA-related mRNA levels in the PFC of schizophrenia 
subjects.  
Aside from GAD67 (B), the age by diagnosis interactions were not statistically significant for any of the GABA-
related mRNA levels examined that were altered in schizophrenia (A, C-F). For each panel, comparison subjects are 
shown in open black circles and schizophrenia subjects in filled black circles. Gray solid and black dashed lines 
indicate lines of best fit for comparison and schizophrenia subjects, respectively. F- and p-values represent the age 
by diagnosis interaction statistics. 
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In schizophrenia subjects, the potential age by diagnosis interaction on GAD67 mRNA 
levels could reflect an additive effect of illness duration in the schizophrenia subjects. Thus, the 
effects of age on GAD67 mRNA expression were evaluated in schizophrenia subjects using a 
regression model to estimate the age effect on GAD67 mRNA expression before and after 
clinical onset (2.2.3). In schizophrenia subjects, the estimated values of the slopes of the change 
in GAD67 mRNA with age did not differ before (β�1s=-0.000026) and after (β�2s=-0.00025) 
clinical onset (p=0.44), suggesting that age has a constant effect on GAD67 mRNA levels in 
schizophrenia subjects.  
Together, our findings suggest that changes in GABA-related transcripts in schizophrenia 
are not a consequence of illness chronicity. 
 
2.3.2 Postnatal trajectories of GABA-related transcripts in monkey PFC 
To investigate the alternative possibility that altered cortical GABA-related mRNA levels reflect 
abnormalities in development that occurred before clinical illness onset, we determined the 
normative postnatal developmental trajectories of these GABA-related transcripts in monkey 
PFC. For markers of GABA neurotransmission, mRNA levels were positively correlated with 
age during postnatal development for vGAT (r=0.308, p=0.031), GAD67 (r=0.285, p=0.047), 
and GABAA α1 (r=0.592, p<0.001) mRNAs, and did not change with age for GAT1 mRNA 
(r=0.111, p=0.449) (Figure 10A-D). The mean mRNA levels in the adult group were 
significantly higher than in the perinatal group for vGAT (+24%), GAD67 (+46%), GABAA α1 
(+78%), but not for GAT1 (Figure 10E-H). For markers of GABA neuronal populations, mRNA 
levels were positively correlated with age for PV (r=0.378, p=0.007), negatively correlated with 
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age for SST (r=-0.416, p=0.003), and did not differ with age for CR (r=-0.165, p=0.256) (Figure 
11A-C). The mean levels in the adult group were significantly higher than in the perinatal group 
for PV (+790%), lower for SST (-33%) and did not differ for CR (Figure 11D-F). 
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Figure 10. Postnatal developmental trajectories of transcripts regulating GABA neurotransmission in rhesus 
monkey PFC.  
For panels A-D, the black line indicates least squares line of best fit; and Pearson’s correlation coefficient (r) and 
corresponding p-value are indicated for each panel on the left. For panels E-H, the black bars indicate group means. 
Age groups that do not share the same letters are significantly different (p<0.05). 
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Figure 11. Postnatal developmental trajectories of GABA neuronal populations in rhesus monkey PFC.  
For panels A-C, the black line indicates least squares line of best fit; and Pearson’s correlation coefficient (r) and 
corresponding p-value are indicated for each panel on the left. For panels D-F, the black bars indicate group means. 
Age groups that do not share the same letters are significantly different (p<0.05). 
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Given that a number of environmental exposures from birth through adolescence are 
associated with increased risk for schizophrenia (van Os et al., 2010), and may have a 
particularly strong influence on neural circuits during sensitive periods of cortical development 
(Hensch, 2005), we determined when during postnatal development transitions in the expression 
levels of GABA-related mRNAs might occur. From the perinatal to childhood period, vGAT 
(+32%), PV (+580%), and GABAA α1 (+54%) mRNA levels increased significantly (Table 3). 
GABAA α1 mRNA expression also increased significantly from adolescence to adulthood 
(+12%), albeit more modestly than the earlier rise. GAD67 mRNA increased progressively from 
the perinatal to adult periods, although most of the rise occurred during the perinatal to 
adolescence periods (+12%). SST mRNA decreased significantly from the perinatal to childhood 
and childhood to adolescence periods (-17% and -18%, respectively). Taken together, the 
majority of GABA-related transcript expression changes were most prominent during the 
perinatal to childhood age periods in monkey PFC. 
Table 3. Timing of the largest changes in PFC GABA mRNA levels 
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2.4 DISCUSSION 
We report modest but significantly lower tissue levels of vGAT and GABAA α1 mRNAs in the 
PFC of schizophrenia subjects. Given these and other recently reported GABA-related transcript 
abnormalities from the same subject cohort (Curley et al., 2011; Volk et al., 2012a), we sought 
to determine whether altered expression of GABA-related mRNAs in schizophrenia could reflect 
the consequences of a chronic illness. Our analyses suggest that neither factors frequently 
comorbid with a diagnosis of schizophrenia nor duration of clinical illness accounted for the 
observed alterations in GABA-related gene expression.  
To explore an alternative possibility that alterations in cortical GABA-related transcripts 
in schizophrenia might reflect developmental disturbances, we determined the postnatal 
developmental trajectories of GABA-related transcripts in the PFC from healthy rhesus 
monkeys. From birth through adulthood the levels of vGAT, GAD67, GABAA α1 and PV 
mRNAs significantly increased, SST mRNA significantly decreased, and GAT1 and CR mRNAs 
remained unchanged. These developmental patterns generally matched those previously reported 
in human PFC (Huang et al., 2007; Duncan et al., 2010; Fung et al., 2010). 
Interestingly, for most transcripts the change in levels with development was in the 
opposite direction of the difference observed between schizophrenia and comparison subjects. 
For example, levels of vGAT, GAD67, GABAA α1 and PV mRNAs all significantly increased 
during postnatal development, and subjects with schizophrenia showed lower expression of these 
transcripts. In contrast, CR mRNA levels decrease significantly during postnatal development in 
human PFC (Fung et al., 2010) and were recently reported to be higher in subjects with 
schizophrenia (Volk et al., 2012a). Finally, transcripts, such as GAT1, that did not change in 
expression level across postnatal development were not altered in schizophrenia. Together, these 
  52 
comparisons suggest the hypothesis that expression patterns of GABA-related transcripts in 
schizophrenia reflect blunted or incomplete developmental trajectories, resulting in a failure to 
achieve normal, mature mRNA levels.  
This idea of an incomplete maturation of cortical GABA-related transcripts in 
schizophrenia is supported by previous findings in the literature. For example, the GABAA α2 
subunit declines across postnatal development in monkey PFC (Hashimoto et al., 2009) and is 
higher in the PFC of schizophrenia subjects (Beneyto et al., 2011), whereas the GABAA δ 
subunit shows exactly the opposite pattern in development and in schizophrenia (Maldonado-
Aviles et al., 2009). In addition, the µ-opioid receptor, which is selectively expressed by 
parvalbumin neurons (Drake and Milner, 1999; Drake and Milner, 2002; Stumm et al., 2004) and 
suppresses GABA release when activated (Drasbek et al., 2007; Drasbek and Jensen, 2006), 
declines with postnatal development and is higher in schizophrenia (Volk et al., 2012b). 
Furthermore, expression patterns of alternatively-spliced transcripts of the GAD1 gene are also 
consistent with this hypothesis; GAD67 mRNA increases and GAD25 mRNA decreases 
normally during early postnatal development of human PFC, but in schizophrenia subjects, the 
relative levels of GAD67 and GAD25 mRNAs were lower and higher, respectively, than in 
matched comparison subjects (Hyde et al., 2011).  
However, not all GABA-related transcripts with altered expression in schizophrenia fit 
the pattern predicted by the incomplete maturation hypothesis. For example, SST mRNA levels 
are lower in the PFC of subjects with schizophrenia (Hashimoto et al., 2008a; Fung et al., 2010) 
but this transcript undergoes a pronounced decline with age that begins during early postnatal 
development and persists throughout adulthood both in macaques and humans (Fung et al., 
2010). The fact that cortical SST mRNA levels are also lower in other psychiatric disorders 
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(Sibille et al., 2011) suggests that the altered expression of this transcript in schizophrenia may 
be driven by factors that are common to these disease processes and thus does not reflect early 
developmental events. 
In the present study, four of the five cortical GABA transcripts that changed during 
postnatal development showed the most notable changes in expression levels during the perinatal 
to childhood transition (Table 3). A number of perinatal and childhood environmental exposures 
such as birth complications and urbanicity have been associated with an increased risk for 
developing psychosis (van Os et al., 2010; Lewis and Levitt, 2002). We also observed increases 
in GAD67 and GABAA α1 mRNA levels during adolescence in monkeys, and a potential 
sensitive period in PFC development when factors such as cannabis use might contribute to an 
increased liability to schizophrenia (Moore et al., 2007). Interestingly, GABA neurons are 
involved in shaping the maturation of cortical circuits during these same developmental periods 
(Le Magueresse and Monyer, 2013). In concert, these data suggest that PFC development 
encompasses multiple sensitive periods during which adverse environmental factors could 
pathologically alter the developmental trajectories of GABA neurons in individuals later 
diagnosed with schizophrenia. 
The idea that GABA-related transcripts might be particularly vulnerable is consistent 
with findings that GABA neurotransmission can powerfully affect critical or sensitive periods in 
cortical development (Hensch, 2005; Le Magueresse and Monyer, 2013). For example, the 
timing of the critical period for the development of binocular vision can be manipulated by the 
enhancement or reduction of GABA transmission in visual cortex (Hensch, 2005), especially via 
GABAA α1-containing neurons (Fagiolini et al., 2004) postsynaptic to PV-containing GABA 
neurons (Nusser et al., 1996). These findings, along with our results that show substantial 
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increases in GABAA α1 and PV mRNA levels during postnatal development, suggest that PV-
containing inputs to GABAA α1-containing postsynaptic structures may be especially susceptible 
to environmental exposures during development. Therefore, our results of lower GABAA α1 and 
PV (Volk et al., 2012a) mRNA levels in schizophrenia may reflect earlier disturbances in 
specific neural circuits during sensitive periods of postnatal development. 
It is important to note that not all of the findings of the present study are in agreement 
with some reports in the literature. For example, recent postmortem studies (Duncan et al., 2010; 
Fung et al., 2011a) using a different subject cohort failed to find the significantly lower levels of 
vGAT and GABAA α1 mRNAs observed in the present study. This discrepancy could reflect 
differences in subject composition of the cohorts since we recently reported that altered 
expression of GABA-related transcripts is particularly marked in a subset of individuals with 
schizophrenia (Volk et al., 2012a). In addition, the absence of a change during postnatal 
development in calretinin mRNA in monkey PFC is not consistent with the reported trajectories 
of calretinin mRNA and protein in human PFC (Fung et al., 2010). Since CR is expressed in 
~40% of GABA neurons in the macaque and human PFC, and these GABA neurons constitute a 
morphologically heterogeneous population of neurons, species-specific differences in the 
development and adult distribution of calretinin levels are possible (Hof et al., 1999).  
In concert, our findings, and those of other published studies, suggest that the altered 
expression of certain GABA-related transcripts in the PFC of subjects with schizophrenia are not 
the consequence of cumulative illness effects and may be due to blunted or incomplete 
developmental trajectories of these transcripts. Together, these findings provide another line of 
evidence supporting the idea that schizophrenia is a disorder of cognitive development, and they 
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provide clues as to what molecular systems might be targeted for preemptive interventions in at 
risk individuals, and when such interventions might be most effective.   
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3.0  REPEATED THC EXPOSURE DURING ADOLESCENCE INDUCES 
ALTERATIONS IN MARKERS OF GABA TRANSMISSION IN MONKEY 
PREFRONTAL CORTEX 
Hoftman GD, Bazmi HH, Lewis DA. Alterations in markers of GABA transmission in the 
prefrontal cortex from THC-treated monkeys. In Preparation.  
3.1 INTRODUCTION 
Marijuana (and other forms cannabis) is, by far, the most commonly used illicit drug in America. 
In 2012, 15% of 8th graders (13-14 year olds), 34% of 10th graders (15-16 year olds), and 45% of 
12th graders (17-18 year olds) reported lifetime use of marijuana (Johnston L. D., 2013). In 
addition, the perception that cannabis can be harmful has decreased, the accessibility increased, 
and use has increased among adolescents (Johnston L. D., 2013). Interestingly, the 
administration of Δ9-tetrahydrocannibinol (THC), the principal psychoactive component in 
cannabis (Freund et al., 2003), impairs working memory performance in adults (Volkow et al., 
1996; D'Souza et al., 2004). Since performance of spatial working memory tasks becomes 
substantially more accurate and faster in humans during adolescence (Luna et al., 2004), this 
growing population of cannabis users (Johnston L. D., 2013) may be particularly sensitive to the 
effects of THC on working memory development. Findings from epidemiological studies support 
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this idea showing repeatedly that cannabis use during early adolescence is associated with a 
dose-dependent increased risk for schizophrenia (Henquet et al., 2005a; Stefanis et al., 2004; 
Arseneault et al., 2002; van Os et al., 2002; Zammit et al., 2002). In addition, chronic exposure 
of immature animals to cannabinoids results in long-lasting alterations in working memory 
(Schneider, 2003 #1218; O'Shea et al., 2004), which is partly mediated by the PFC (Goldman-
Rakic, 1995). Thus, understanding the biological mechanisms of this relationship is an important 
public health issue.  
Adolescence is a period of development that is associated with refinements in PFC neural 
circuits that are correlated with improvements in the manipulation of information during working 
memory tasks (Luna, 2009). The neural basis for the protracted maturation of working memory 
performance has been attributed, at least in part, to age-related increases in dorsolateral PFC 
activity (Goldman-Rakic, 1995). The development of spatial working memory and PFC activity 
temporally parallels the structural maturation of PFC circuitry during childhood and adolescence, 
with dynamic changes occurring at GABA neuron connections (Cruz et al., 2003; Cruz et al., 
2009a; Erickson and Lewis, 2002). For example, mRNA levels of GAD67 and GAD65 have 
been reported to increase throughout childhood and adolescence in primate PFC (Huang et al., 
2007; Hyde et al., 2011). Levels of PV mRNA also increased during the infancy-childhood 
transition (Figure 11). In the monkey PFC, CB1R are enriched at CCKb axon terminals (Eggan 
et al., 2010; Freund et al., 2003), which make direct synaptic connections with PVb (Karson et 
al., 2009). In concert, these findings suggest that adolescence may be a sensitive period for the 
effects of chronic cannabis exposure on maturing PFC GABA circuitry. 
Recently, our group reported adverse residual effects (from 7 hours to 20 days; versus 
acute effects within 6 hours of exposure) of repeated THC exposure on spatial working memory 
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in adolescent monkey PFC. Importantly, these effects occurred at doses that mimic human 
recreational use of cannabis (Verrico et al., 2012). Therefore, we tested the hypothesis that 
chronic THC exposure during adolescence results in the disruption of GABA-related gene 
expression. Using quantitative real-time PCR from adolescent monkey PFC tissue, we report that 
GAD65 mRNA expression was higher by 15% in THC-treated animals relative to vehicle-treated 
matched comparisons, and PV mRNA was lower by 19%. In contrast, levels of GAD67, CB1R 
and CCK mRNAs did not differ between groups. 
3.2 METHODS 
3.2.1 Animals 
Fourteen experimentally naïve, male rhesus macaque (Macaca mulatta) monkeys were acquired 
as a single cohort. Since spatial working memory performance increasingly becomes dependent 
upon PFC activity beginning at 12 months of age and continuing through ~36 months of age, 
animals were trained to achieve comprehension on two working memory tasks by 28 months of 
age (Verrico et al., 2011). These animals were housed as previously described in accordance 
with the USDA and NIH Guidelines for Animal Care and with the approval of the University of 
Pittsburgh’s IACUC. 
 Behavioral tasks and intravenous administration of THC have been described in detail 
elsewhere (Verrico et al., 2012; Verrico et al., 2011). Briefly, animals were trained to respond to 
computerized touchscreens and to perform a spatial delay response task and an object recall 
working memory task. These two tasks were chosen since spatial working memory performance 
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depends upon the dorsolateral PFC, which matures later than the ventrolateral PFC (Conklin et 
al., 2007; Paus, 2005), while object recall performance depends upon the ventrolateral PFC, 
(Wilson et al., 1994; Funahashi et al., 1989; Goldman et al., 1971; Goldman and Rosvold, 1970). 
The fourteen trained male adolescent monkeys were matched for baseline cognitive performance 
and assigned to a THC- or vehicle-treatment group. THC was suspended in a vehicle containing 
1% Tween-80 and 0.9% saline (Verrico et al., 2012). THC/vehicle administration was initiated at 
~28 months of age and doses of either 120 (n=3) or 240 (n=4) μg/kg were administered daily for 
5 days each week and continued until one month before the animals were sacrificed.  
3.2.2 Tissue 
Postpubertal animals ranging in age from 40-44 months of age (Table 4) were perfused 
transcardially with ice-cold modified artificial cerebrospinal fluid following deep anesthesia 
induced with ketamine and pentobarbital and the brains were removed. For all animals, the right 
hemisphere of each brain was blocked coronally and each block was frozen and stored at -80oC. 
         Table 4. Adolescent male rhesus monkeys used in the THC study 
 
Pair Subject ID Sex Age at Sacrifice (Months) Treatment
MJ219 M 41 Vehicle
MJ315 M 40 THC
MJ401 M 41 Vehicle
MJ320 M 41 THC
MJ324 M 42 Vehicle
MJ327 M 41.5 THC
MJ508 M 41 Vehicle
MJ421 M 41 THC
MJ407 M 42.5 Vehicle
MJ522 M 41 THC
MJ607 M 42 Vehicle
MJ512 M 42 THC
MJ523 M 43.5 Vehicle
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Gray matter from adjacent sections containing the principal sulcus from PFC area 46 was 
separately collected into a tube containing TRIzol reagent using a method that ensured minimal 
white matter contamination and excellent RNA preservation (Volk et al., 2012a). Primer sets 
were designed against the macaque sequences of GAD65, PV, GAD67, CB1R and CCK, as well 
as three reference genes, β-actin, cyclophilin-A, GAPDH, which exhibited stable relative 
expression levels across in both subject groups. qPCR reactions were carried out using the SYBR 
1 Green reporter as described in (2.2.1 and 2.2.2). 
3.2.3 Statistics 
Paired t-tests were used to analyze the experimental group mean differences of the target 
transcript expression ratio. Pearson’s correlation coefficients were calculated to determine 
whether a linear relationship existed between changes in GAD65 and PV mRNA levels. 
3.3 RESULTS 
In PFC area 46 from postpubertal animals, we found that levels of GAD65 mRNA were higher 
by 16% (t6 = -3.971; p = 0.007) in experimentally matched pairs of THC-treated animals 
(reported as expression ratio mean ± SD; 0.0028 ± 0.0003) relative to vehicle-treated 
comparisons (0.0024 ± 0.0002). Levels of PV mRNA were lower by 18%, but did not reach 
statistical significance (t6 = 1.12; p = 0.31) in THC-treated (0.054 ± 0.011) versus vehicle-treated 
(0.045 ± 0.016) subjects. However, closer examination revealed that in Pair 3, PV mRNA levels 
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were much higher in the THC-treated animal than its matched comparison. Furthermore in Pair 
3, GAD65 mRNA levels did not differ between the THC-treated and comparison animals. An 
additional paired t-test analysis performed excluding pair 3 showed that GAD65 mRNA levels 
were higher by 19% (t5 = -6.03; p = 0.002) and PV mRNA levels were lower by 30% (t5 = 2.46; 
p = 0.058) in THC-treated animals (GAD65: THC-treated = 0.0028 ± 0.0002; vehicle-treated = 
0.0023 ± 0.0003; PV: THC-treated = 0.040 ± 0.012; vehicle-treated = 0.056 ± 0.011) (Figure 
12). In contrast, levels of GAD67, CB1R and CCK mRNAs did not significantly differ (All t6 < 
0.53; p > 0.61) between experimental groups, with or without Pair 3 included in the analysis. 
 In order to determine whether a relationship existed between GAD65 and PV mRNA 
expression, we examined Pearson’s correlations between them. The within-pair percent 
differences of GAD65 and PV mRNA levels were significantly negatively correlated (r=-0.768; 
p=0.044) (Figure 13). 
 In chapter 2, we reported the postnatal developmental trajectories of PV and GAD67 
mRNA in monkey PFC. Here in the same PFC region from the same animals, we report that 
GAD65 mRNA levels increase across postnatal development, while CCK mRNA levels did not 
differ across the ages studied (Figure 14).  
 
  62 
 
Figure 12. Higher GAD65 and lower PV mRNA levels in the PFC in THC-treated animals 
Panels (A) and (B) GAD65 mRNA levels with 7 and 6 pairs, respectively. Panels (C) and (D) PV mRNA levels with 
7 and 6 pairs, respectively. Paired t-tests were used to determine statistical significance. Asterisk (*) indicates the 
animal pair (pair 3) in which the THC-treated subject had higher PV mRNA levels by 70% and was thus excluded 
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Figure 13. Within-pair percent differences in GAD65 and PV mRNA levels is significantly correlated 
Pearson’s correlation coefficient was used to determine the correlation. For analysis not including pair 3, r = -0.567 
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Figure 14. GAD65 mRNA levels increase and CCK mRNA levels do not significantly change during postnatal 
development in monkey PFC 
In (A) and (B), the black line indicates least squares line of best fit; and Pearson’s correlation coefficient (r) and 
corresponding p-value are indicated for each panel on the left. In (C) and (D), the black bars indicate group means. 
Age groups that do not share the same letters are significantly different (p<0.05). 
 
3.4 DISCUSSION 
In the dorsolateral PFC area 46 in post-pubertal monkeys, we found that the residual effects of 
repeated THC administration to adolescent monkeys resulted in a 15% increase in GAD65 
mRNA levels, and a 19% decrease in PV mRNA levels. In contrast, mRNA levels of GAD67, 
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CB1R and CCK did not differ between THC-treated animals and their matched vehicle-treated 
comparison subject pairs. The within-pair percent differences in GAD65 and PV mRNA levels 
were correlated such that cases where the THC-treated animal had higher GAD65 mRNA levels 
also tended to have lower PV mRNA levels relative to the vehicle-treated animal. 
 These same animal pairs had performed spatial delay response and object recognition 
working memory tasks throughout the course of THC/vehicle-treatment (Verrico et al., 2012; 
Verrico et al., 2011). THC-treated animals were less accurate with their responses on the spatial 
delay response task relative to their matched comparison animals, and their developmental 
improvement in performance was also delayed (Verrico et al., American Journal of Psychiatry, 
In Revision). In contrast, both animal groups performed similarly on the object recognition 
working memory task. Our findings of a change in GABA-related gene expression that 
accompanied a delay in accuracy on the spatial working memory task suggest that dorsolateral 
PFC GABA neuron alterations in response to chronic THC administration may underlie the 
poorer performance in these animals. However, given the large variability in behavioral 
performance across sessions and between monkey pairs, a direct correlational assessment of the 
behavioral measures with GAD65 and PV mRNA levels was not possible.  
 The functional consequences of increased GAD65 mRNA levels and decreased PV 
mRNAs in the PFC depend upon the cell type-specific effects of THC administration. The 
inverse correlations of GAD65 and PV mRNA levels suggest that these alterations may be 
occurring within the same cell type. Since CCKb are the only GABA neurons in the monkey 
PFC that are enriched with terminal CB1R (Eggan et al., 2010), THC administration would be 
expected to reduce GABA release from these terminals (Freund et al., 2003). Less GABA 
release could either reduce inhibition onto PVb receiving direct connections from CCKb, or 
  66 
reduce inhibition to the perisomatic region of target pyramidal neurons. Since cortical PV 
neurons receive a substantial amount of excitatory input onto their dendrites (Melchitzky and 
Lewis, 2003), the combined reduction of inhibition directly from CCKb inputs and indirectly 
from excitatory inputs could result in PVb neuron hyperactivity. Given the importance of the 
normal development and timing of PV neuron activity for the production of gamma oscillations 
(Freund and Katona, 2007; Uhlhaas et al., 2009), disruptions in the adolescent refinement of PFC 
circuits could underlie cognitive dysfunction in schizophrenia (Uhlhaas and Singer, 2010).  
Interestingly, GAD65 protein is enriched in the axon terminals of both CCKb and PVb, 
while CB1R and PV proteins are localized to terminals of separate GABA neuron 
subpopulations (Fish et al., 2011). In contrast, GAD67 protein is detectable by 
immunofluorescence in PVb but not in CCKb axon terminals. While GAD67 and GAD65 both 
synthesize GABA, their functions appear to be quite nuanced. Aside from their cell type-specific 
distributions, GAD67 and GAD65 have distinct intracellular distributions. GAD67 is a cytosolic 
enzyme that is found throughout the cell including at axon terminals, while GAD65 is primarily 
enriched at axon terminals. Both GAD isoforms are regulated by the pyridoxal 5’-phosphate 
cofactor that activates the enzyme when bound, although GAD67 is normally saturated with 
cofactor and as a result is constitutively active (Kaufman et al., 1991). In contrast, GAD65 is 
highly regulated by this cofactor switch since it exists largely in the low bound inactive form 
(Kaufman et al., 1991). Instead of a cofactor switch regulation, GAD67 appears to be 
dynamically regulated by transcription based on neural activity (Lau and Murthy, 2012; Pinal 
and Tobin, 1998). Germline deletion of GAD67 in mice resulted in a lethal phenotype due to 
severe cleft palate along with a dramatic reduction in GAD enzymatic activity and GABA levels 
at birth (Asada et al., 1997). In contrast, deletion of the GAD65 gene altered GABA levels much 
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more subtly (Asada et al., 1996). However, germline deletion of GAD65 results in an increased 
susceptibility to seizures, and GAD65 appears to be crucial for synthesizing appropriate levels of 
GABA during conditions of high synaptic demand, like gamma oscillations (Battaglioli et al., 
2003; Patel et al., 2006; Tian et al., 1999). Thus, if the THC-mediated reduction of GABA 
release occurs at CCKb terminals, then a subsequent increase in the intracellular concentration of 
presynaptic GABA and reduction of GAD65 protein levels could underlie the observed increase 
in GAD65 mRNA levels. Such a potential reduction in GAD65 protein could affect the timing of 
CCKb inhibition onto PVb and pyramidal neurons, thus disrupting network oscillations that 
require the temporally coordinated activity of these neuron populations. 
Alternatively, systemic administration of THC could result in a non-specific blanket 
suppression of neurotransmitter release from CB1R containing axon terminals, whether these 
terminals produce GABA or glutamate for neurotransmission. This network level suppression of 
transmitter release may then alter the levels and patterns of activity necessary for the proper 
maturation of PVb. Since molecular markers of PV neurons, but not CCK neurons, undergo 
substantial changes during adolescence, PVb may be particularly vulnerable to the effects of 
THC on neural network refinement. Thus, the alterations in GAD65 and PV mRNA levels may 
actually occur in PVb cells that are actively being refined during the time period of THC 
administration. Alterations in GAD65 activity in PVb axon terminals would likely have an 
impact on gamma oscillations since GAD65 activity is thought to be important for periods of 
high synaptic GABA demand (Patel et al., 2006; Tian et al., 1999) and PV neurons are critical in 
determining the power of gamma oscillations (Sohal et al., 2009; Cardin et al., 2009). Cell type-
specific protein studies will be needed to address these possibilities. 
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One possibility for the lack of detectable changes in GAD67 mRNA is that levels 
normalized during the one-month recovery period between final THC administration and 
sacrifice. Since GAD67 mRNA expression is particularly sensitive to neuronal activity and it is 
found in numerous GABA synthesizing cell types like the calretinin-containing neurons, another 
possibility is that a residual effect of chronic THC administration on GAD67 mRNA levels in 
PVb neurons may not have been large enough to detect. In addition, our observation that CB1R 
mRNA expression was not altered after chronic THC administration could reflect the possibility 
that this receptor was altered functionally by decoupling with its G-protein rather than a 
reduction in protein levels. Alternatively, since CB1R are located in CCKb cells, perhaps these 
particular neurons are not chronically altered in the face of repeated THC administration since 
these cells already appear to have reached functional maturity prior to adolescence (Oeth and 
Lewis, 1993). 
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4.0  PARVALBUMIN-CONTAINING CHANDELIER AND BASKET CELL 
BOUTONS HAVE DISTINCTIVE MODES OF MATURATION IN MONKEY 
PREFRONTAL CORTEX 
Adapted from: *Co-first authors: Fish KN*, Hoftman GD*, Sheikh W, Kitchens M, Lewis DA 
(2013). Parvalbumin-containing chandelier and basket cell boutons have distinctive modes of 
maturation in monkey prefrontal cortex. Journal of Neuroscience. 33: 8352-8358. 
4.1 INTRODUCTION 
The postnatal development of GABAergic circuitry in the monkey prefrontal cortex (PFC) is a 
protracted process that extends into early adulthood (Hoftman and Lewis, 2011). This process 
includes the establishment and maturation of precise connections among neuronal populations. 
For example, the axons of chandelier (axoaxonic) cells (PVch) exclusively target the axon initial 
segment (AIS) of pyramidal neurons (Szentagothai and Arbib, 1974); the convergence of axons 
from multiple PVch onto a single pyramidal neuron AIS forms a distinctive, vertically-oriented 
array of boutons termed a cartridge (Lewis and Lund, 1990). Many cortical PVch contain the 
calcium binding protein parvalbumin (PV) (DeFelipe et al., 1989), and the density of cartridges 
detectable by PV immunoreactivity decreases between 3 mo and adulthood in monkey PFC 
(Cruz et al., 2003). In contrast, the density of PV-immunoreactive (IR) boutons that do not 
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belong to cartridges, and which presumably arise from PV-containing basket cells (PVb), 
significantly increases between these same ages (Erickson and Lewis, 2002). Both of these 
findings appear to conflict with the results of other studies indicating that the overall densities of 
GABAergic synapses in monkey PFC do not undergo postnatal developmental refinements. 
Specifically, the density of all symmetric (putatively inhibitory) synapses does not change 
between 3 months and adulthood (Bourgeois et al., 1994), and the density of GABA membrane 
transporter 1 (GAT1)-IR puncta appears to remain constant (Erickson and Lewis, 2002). 
This apparent conflict might be resolved by opposite but equivalent changes in the 
densities of PVch and PVb boutons across postnatal development such that the overall density of 
inhibitory boutons and synapses does not change. Alternatively, the apparent changes with age in 
the densities of PVch cartridges and PVb boutons could reflect inverse developmental shifts in 
bouton levels of PV protein such that PVch and PVb boutons become less and more detectable 
with age, respectively. In order to discriminate among these alternatives, we used quantitative, 
multi-label, fluorescence confocal microscopy to assess the density of, and relative PV protein 
levels in, the boutons of PVch and PVb in the PFC of 3 month old (3 mo) and adult monkeys. 
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4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Macaque (Macaca fascicularis), monkeys (3 mo (3 females) and adult (156-192 mo; 2 female 
and 1 male)) were anesthetized and then perfused transcardially as previously described (Cruz et 
al., 2003). Brains were immediately removed, and coronal blocks (5 to 6 mm thick) were cut and 
stored in a cryoprotectant solution at –30oC (Cruz et al., 2003). Sections (40 µm) were 
exhaustively cut from left hemisphere blocks containing the entire rostral-caudal extent of the 
principal sulcus (area 46). All experimental procedures were conducted in accordance with the 
NIH Guide for the Care of Animals and with the approval from the University of Pittsburgh’s 
IACUC. 
4.2.2 Antibodies and immunocytochemistry 
Two sections per monkey, 1 mm apart, were taken from the middle 1/3 of the principal sulcus 
(Figure 15) and processed as follows. Sections were permeabilized with 0.3% Triton X-100 in 
phosphate buffered saline (PBS) for 30 min at room temperature (RT), rinsed, and blocked with 
20% donkey serum for 2 hr at RT. Sections were then incubated for ~72 hr at 4ºC in PBS 
containing 3% donkey serum and the following antibodies: PV [sheep, R&D Systems; 1:100; 
(Kagi et al., 1987)] and the vesicular GABA transporter [vGAT; guinea pig, Synaptic Systems; 
1:500; (Guo et al., 2009)], which concentrates in GABAergic boutons (Chaudhry et al., 1998), to 
identify boutons; the GABAA receptor subunit γ2 [γ2; rabbit, Synaptic Systems; 1:400; (Fritschy 
and Mohler, 1995)] to identify postsynaptic sites of GABA boutons; and ankyrin-G [AnkG; 
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mouse, Santa Cruz; 1:100; (Wang and Sun, 2012)] and neuronal nuclei [NeuN; mouse, 
Millipore; 1:500; (Mullen et al., 1992)] to identify the AIS and soma, respectively, of pyramidal 
neurons. Sections were then rinsed for 2 hr in PBS, incubated with secondary antibodies 
(Donkey; 1:500) conjugated to Alexa 405, 488, 568, 647 (Invitrogen), or biotin (Fitzgerald) for 
24 hrs in PBS at 4ºC. Sections were then rinsed and a tertiary incubation (24 hr at 4ºC) with 
streptavidin 405 was performed to label the biotinylated secondary antibody. The final 
fluorescence detection channel assignment (excitation) was: vGAT (405nm), AnkG and NeuN 
(488nm), PV (568nm), and GABAA γ2 (647nm). Note that AnkG and NeuN, which were both 
detected using mouse primary antibodies, were visualized in the same channel. 
4.2.3 Microscopy 
Image stacks (512x512 pixels; 0.25 μm z-step) were collected on an Olympus IX71 microscope 
(Center Valley, PA) controlled by SlideBook 5.0 (3I, Denver, CO) and equipped with an 
Olympus spinning disk confocal, Hamamatsu C9100 EM-CCD (Bridgewater, NJ), and LEP 
BioPrecision2 XYZ motorized stage (Hawthorne, NY) using a 60X 1.42 N.A. objective. 
Sampling was confined to layers 2-4 [defined as 10-60% of the distance from pial surface to 
white matter (Pierri et al., 1999)] of PFC area 46 (Figure 15) because the density of PV-IR 
cartridges is highest at 3 mo and lowest in adult monkeys within these layers (Cruz et al., 2003); 
in contrast, the density of detectable PV-IR boutons was previously reported to be low in 3 mo 
and highest in adult monkeys in these same layers (Erickson and Lewis, 2002). Sites were 
systematic randomly sampled using a grid of 190 x 190 µm2 with stacks collected from 20 
randomly selected sites per section. 
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4.2.4 Image processing 
Image stacks were taken using optimal exposures (greatest dynamic range/no saturated pixels), 
exposure corrected, deconvolved using the AutoQuant adaptive blind deconvolution algorithm, 
and segmented. Within each field, AIS were manually traced only if they were considered to be 
completely visualized as indicated by 1) continuity across z planes; 2) a proximal end adjacent to 
a clearly defined NeuN-IR soma; 3) a distal end, defined by tapering of the AnkG signal to the 
width of an axon; and 4) the entire AIS was contained within a virtual sampling box. The virtual 
sampling box started and ended 1 z-plane from the top and bottom of the image stack, 
respectively, and had x-y start/end coordinates that were located 20 pixels from any edge. AIS 
length was calculated by measuring the distance between unique points at the soma-hillock 
boundary, the centroid, and distal end of the AnkG-IR AIS profile. 
4.2.5 Definitions of synaptic structures 
Intensity/morphological segmentation was used to make object masks for each IR puncta, 
identified as small (0.03 to 1 µm3), distinct fluorescing objects (Fish et al., 2011). A GABAergic 
bouton was defined as a vGAT-IR puncta adjacent to a GABAA receptor γ2-IR cluster. Mask 
operations were then used to classify the different bouton populations. Specifically, a PV bouton 
was defined as a PV object mask that contained the center of a vGAT object mask (PV/vGAT-
IR), which overlapped a GABAA receptor γ2 object mask. Importantly, the presence of vGAT 
excludes the possibility that it is a thalamic bouton. PV boutons adjacent to γ2-IR puncta not 
associated with an AnkG-labeled AIS were classified as PVb, while those adjacent to γ2-IR 
puncta within AnkG-labeled AIS were classified as PVch. ChCPVneg boutons were defined as 
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those GABAergic boutons adjacent to γ2-IR puncta within AnkG-labeled AIS that could not be 
represented by a PV object mask. Importantly, all GABAergic boutons that overlapped with γ2-
IR puncta within AnkG-labeled AIS were classified as being either a PVch or a ChCPVneg bouton. 
4.2.6 Statistics 
Diagnostic statistics were used to confirm that the data were normally distributed. Independent t-
tests were used to compare dependent measures between age groups. In all analyses, the statistics 
were performed on the mean values for individual monkeys (N=3 per age group) determined by 
first averaging data within stack, then averaging stack means within section, and finally 
averaging means across sections.  
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4.3 RESULTS 
4.3.1 The density of GABAergic boutons does not differ between 3 mo and adult 
monkeys. 
The mean (±SD) density of GABAergic boutons in layers 2-4 of the PFC neuropil did not differ 
(t [4]=0.731, P=0.505) between 3 mo (0.045±0.006 boutons/µm3) and adult (0.041±0.004 
boutons/µm3) animals. Because density measures may be confounded by age-related changes in 
PFC volume (Erickson and Lewis, 2002), we also determined the number of GABAergic 
boutons per NeuN-IR neuron, which did not differ (t [4]=0.939, P=0.401) between age groups. 
4.3.2 The mean number of PVch boutons per AIS, but not of PVb boutons per neuron, is 
lower in adult compared to 3 mo monkeys. 
The mean number of PVch boutons per AIS was 32% lower (t [4]=2.853, P=0.046) in adult 
(10.5±1.7) relative to 3 mo (15.5±2.5) monkeys (Figure 15). Additionally, the magnitude of the 
difference between age groups was similar for chandelier cell boutons that did not appear to 
contain PV (ChCPVneg) (Figure 16). Given that the densities of GAT1- and PV-IR cartridges 
were previously reported to show different patterns of change both within the same layers and 
across layers during postnatal development (Cruz et al., 2003), we performed an additional 
analysis that took layer into account. Specifically, we separated sampling sites based on their 
laminar position into two groups: layers 2-superficial 3 and layers deep 3-4. Although the 
magnitude of the reduction in PVch boutons was similar across layers, there was a two-fold 
greater magnitude of reduction in ChCPVneg boutons in layers 2-superficial 3 compared to layers 
deep 3-4 (Figure 16B). In contrast to PVch boutons, neither the number of PVb boutons per 
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NeuN-IR pyramidal neuron (t [4]=-0.201, P=0.851), nor the density of PVb boutons in the 
neuropil (t [4]=-1.758, P=0.154), differed between 3 mo (244±84 boutons/pyramidal neuron and 
0.0101±0.0013 boutons/µm3, respectively) and adult (254±31 boutons/pyramidal neuron and 
0.0117±0.0008 boutons/µm3, respectively) monkeys. 
To determine if biased sampling could have contributed to the age-related decline in the 
mean number of PVch boutons per AIS, the robustness of our sampling was assessed. Although 
the coefficient of variation for the number of PVch boutons per AIS within adult animals ranged 
from 75% to 129%, the coefficient of error ranged from 5% to 10%, indicating that the obtained 
means are robust estimates of the true population means. In addition, the difference in mean 
number of PVch boutons per AIS between age groups was not accompanied by any change (t 
[4]=-1.289, P=0.267) in PV-IR cell body density, consistent with a prior report (Conde et al., 
1996). These latter findings suggest that the lower number of PVch boutons per AIS in the adult 
animals did not result from a postnatal loss of PVch (Southwell et al., 2012). 
A highly stringent criterion was used to define a PVch bouton, raising the possibility that 
some PVch to pyramidal AIS connections were excluded from the analysis. To ensure that the 
age-related reduction in mean number of PVch boutons per AIS was not confounded by this 
possibility, the mean numbers of PV-IR, vGAT-IR, and γ2-IR puncta that overlapped AIS were 
compared between age groups. The mean numbers of PV-IR and vGAT-IR puncta per AIS 
declined (t [4]=6.028, P=0.004 and t [4]=5.327, P=0.006, respectively) between 3 mo (19.2±2.0 
and 21.8±2.4, respectively) and adult (11.8±0.6 and 14.2±0.7, respectively) animals (Figure 16). 
Likewise, the mean number of γ2-IR puncta per AIS significantly declined (t [4]=3.577, 
P=0.023) between 3 mo (26.7±4.8) and adult (15.3±2.7) animals. The percent declines in γ2-IR, 
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vGAT-IR, and PV-IR puncta per AIS, which ranged from 35%-43%, were similar to the 32% 
age related decline in mean number of PVch boutons per AIS. 
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Figure 15. The mean number of PVch boutons per AIS is decreased in adult compared to 3 mo monkeys 
(A) Lateral view of monkey cortex showing the approximate location (black vertical bar) of the PFC where tissue sections for this 
study were taken. (B) Schematic of a typical coronal section containing the principal sulcus (PS; area 46) at the position along the 
rostral-caudal axis designated by the dotted line in A. The black rectangle designates the laminar location in the ventral bank of the PS 
where analyses were performed. (C) Adult monkey section multi-labeled for NeuN/AnkG, γ2, PV, and vGAT. Single channel and 
merged projection images of a deconvolved image stack (5 z-planes). Arrows–PVch boutons; Arrowheads–PVb boutons. Bar=10 µm. 
(D) Histogram of PVch boutons per AIS in 3 mo (black; mean 15.5) and adult (grey; mean 10.5) monkeys. Arrowheads point to 
respective means. A randomly selected 500 AIS from each age group is displayed. 
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Figure 16. The mean number of puncta immunoreactive for PV, vGAT, or γ2 overlapping AIS is decreased in adult compared 
to 3 mo monkeys 
(A) Single channel images of a deconvolved image stack (5 z-planes) of an adult monkey section multi-labeled for NeuN/AnkG, PV, 
vGAT, and γ2. Solid arrowhead—PVch bouton; open PVch bouton with no visually detectable PV. A 3X zoom of the boxed region is 
shown below each channel. Bar=10 µm. (B) Table showing the mean number of chandelier cell (ChC) boutons per AIS (all ChC), 
ChC boutons classified as containing PV (PVch), and ChC boutons classified as being PV immuno-negative (ChCPVneg). (C) Single 
channel images of a deconvolved image stack (5 z-planes) of an adult monkey section multi-labeled for NeuN/AnkG, PV, vGAT, and 
γ2. Arrows, solid arrowheads, and the open arrowhead point to AIS differentially innervated by PVch. Bar=10 µm. (D) Histograms of 
PV- (mean 3 mo=19.2, adult=11.8), vGAT- (mean 3 mo=21.8, adult=14.2), and γ2- (mean 3 mo=26.7, adult=15.3) IR puncta per AIS 
in 3 mo (black) and adult monkeys (grey). Arrowheads point to respective means. A randomly selected 500 AIS from each age group 
is displayed. 
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AIS innervation by PVch was found to be highly variable in both 3 mo (0 to 42 PVch 
boutons per AIS) and adult (0 to 39 PVch boutons per AIS) monkeys. Considering that the mean 
numbers of PVch boutons per AIS in 3 mo and adult animals were 15.5 and 10.5, respectively, 
these findings suggest that a large number of AIS might not be associated with a 
morphologically detectable cartridge and that the density of detectable PVch cartridges might be 
significantly reduced between 3 mo and adulthood. To assess cartridge density, PV-IR cartridges 
were identified qualitatively by their characteristic morphology and the number of PV-IR 
boutons per AIS was quantified. The PV channel was used to select PV-IR cartridges, and then 
the other channels (vGAT, γ2, and AnkG/NeuN) were used to determine how many boutons 
were present in each cartridge. This approach revealed that PV-IR morphologically-distinct 
cartridges were composed of 12 or more PVch boutons. Of 500 randomly selected pyramidal 
cells from 3 mo monkeys, the AIS of 320 (64%) was innervated by ≥ 12 boutons, while in adult 
monkeys the AIS of only 163/500 (32.6%) pyramidal cells was innervated by ≥ 12 boutons. This 
49% decrease in the number of recognizable cartridges between 3 mo and adult monkeys is 
similar to the previously reported 55% decline using a different method (Cruz et al., 2003; Cruz 
et al., 2009a; Anderson et al., 1995). 
4.3.3 The number of PVch boutons per AIS is positively correlated with AIS size. 
The mean length (t [4]=6.213, P=0.003) of AIS, as determined by AnkG immunoreactivity, was 
~33% shorter in adult (19.7±1.4 µm) than in 3 mo (29.1±2.3 µm) monkeys (Figure 17A). In 
addition, the average AIS surface area determined by AnkG immunoreactivity was significantly 
less (t [4]=4.839, P=0.008) in adult (132±8 µm2) than 3 mo (202±24 µm2) monkeys (Figure 
17B). Furthermore, the number of PVch boutons was positively correlated (3 mo R=0.764, P < 
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0.001; adult R=0.735, P < 0.001) with AIS surface area within monkeys (Figure 17C). 
Importantly, mean AnkG fluorescence intensity in AIS did not differ (t [4]=0.436, P=0.685) 
between adult (2494±231) and 3 mo (2554±67) monkeys, suggesting that group differences in 
AIS length and surface area were not confounded by changes in AnkG fluorescence. 
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Figure 17. The number of PVch boutons per AIS is positively correlated with AIS size 
(A) NeuN and AnkG labeled soma and AIS, respectively, from 3 mo and adult monkeys. The selected neurons are representative of the length differences 
between age groups (see main text). Asterisks designate the axon hillock. Bar=10 µm. (B) Histogram showing the surface area of 500 randomly selected AIS 
from each age group (3 mo black, mean 202; adult grey, mean 132). Arrowheads point to respective means. (C) Scatter plot of 150 randomly selected AIS from 
each age group (3 monkeys/group, 50 AIS/monkey) showing the relationship between AIS surface area and the number of PVch boutons. 
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4.3.4 Relative PV protein levels in PVb boutons, but not in PVch boutons, are 
significantly greater in adult compared to 3 mo monkeys. 
The relative mean protein level of PV per PVb bouton increased significantly by 69% between 3 
mo and adulthood. This increase was accompanied by an increase in the relative mean protein 
level of vGAT (25%) per PVb bouton and in γ2 (35%) relative protein levels in the 
corresponding postsynaptic clusters between 3 mo and adulthood, although neither of these 
changes achieved statistical significance (Table 5). In contrast, relative mean protein levels of 
PV and vGAT per PVch bouton, and γ2 per postsynaptic cluster adjacent to a PVch bouton were 
similar between the two age groups (Table 5). 
 
Table 5. Relative protein levels in PVb and PVch boutons (PV and vGAT) adjacent to postsynaptic clusters 
(γ2) in 3 mo and adult monkeys 
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4.4 DISCUSSION 
Prior reports of a decreased density of PVch axon cartridges (Anderson et al., 1995; Cruz et al., 
2009a; Cruz et al., 2003) and increased density of PV-IR boutons (Erickson and Lewis, 2002) 
over postnatal development in monkey PFC could represent inverse changes in bouton number 
and/or in PV protein levels per bouton. As reported here, the mean number of PVch boutons per 
pyramidal neuron AIS was significantly 32% lower in adult compared to 3 mo monkeys, with no 
group differences in relative mean PV protein levels per PVch bouton. In contrast, the density of 
PVb boutons did not differ between age groups, but the relative mean PV protein levels in PVb 
boutons were nearly 2-fold higher in adults than in 3 mo monkeys. Thus, PVch and PVb appear 
to utilize fundamentally different mechanisms to achieve adult levels of innervation of their 
pyramidal cell targets. 
The result that GABAergic bouton density in the PFC does not differ between 3 mo and 
adult monkeys, along with previous reports that neither the density of symmetric synapses 
(Bourgeois et al., 1994) nor the density of GAT1-IR puncta (Erickson and Lewis, 2002) differed 
between these age groups suggest that GABAergic boutons are not pruned during postnatal 
development. In this context, our finding of an age-related reduction in PVch boutons strongly 
suggests that the pruning of these boutons is cell type-specific, and not detectable when all 
GABAergic boutons are assessed without regard to cell type. 
In this study, AIS mean length and average surface area were ~33% less in adult than in 3 
mo monkeys, consistent with previous reports (Cruz et al., 2009a). Recent studies have shown 
that AIS length/location depend, at least in part, upon network activity (Grubb et al., 2011). 
Interestingly, we found that the number of PVch boutons was positively correlated with AIS 
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surface area. In concert, these findings suggest that the number of PVch inputs onto a given 
pyramidal neuron is also regulated by network activity. 
The distinctiveness of a developmental reduction in the number of PVch boutons may be 
related to their unique role in innervating the AIS of pyramidal neurons where they are 
positioned to regulate action potentials. Interestingly, we found that the number of PVch boutons 
associated with an AIS is highly variable across AIS in both 3 mo (0 to 42 PVch boutons per 
AIS) and adult (0 to 39 PVch boutons per AIS; Figure 15D) monkeys, similar to prior electron 
microscopy studies in adult primates (DeFelipe et al., 1985; Inda et al., 2007). These findings 
raise the possibility that the degree of action potential regulation by PVch differs across subtypes 
of pyramidal neurons. Consistent with this idea, the mean number of inputs to the AIS is greatest 
in callosal-projecting pyramidal cells, intermediate in pyramidal cells providing ipsilateral 
cortical projections, and lowest in corticothalamic pyramidal neurons in monkey neocortex 
(Farinas and DeFelipe, 1991). However, even among pyramidal neurons that share the same 
projection target, the number of PVch inputs to the AIS shows considerable variability (Farinas 
and DeFelipe, 1991). These findings, and those of the present study, reveal a marked 
heterogeneity in the need for PVch regulation of pyramidal neurons, across and within subclasses 
of pyramidal cells, and apparently across development for the same pyramidal cells. Given the 
reported roles of PVch inputs of either hyperpolarizing or depolarizing pyramidal cells based on 
levels of network activity (Woodruff et al., 2011) or of blocking retrograde action currents 
(Dugladze et al., 2012), why some pyramidal cells need a high level of these types of regulation 
and others do not is an important question for future studies. 
In contrast to PVch, relative PV protein levels in PVb boutons were two-fold higher in 
adult compared to 3 mo monkeys. In concert with our finding that PVb bouton density did not 
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differ between age groups, these results suggest that the previously reported increase in PV-IR 
puncta density across postnatal development in monkey PFC results from an age-related rise in 
PV protein levels per PVb bouton and thus an increase in their detectability by standard light 
microscopy. Although the physiological role of Ca2+ buffering by PV is still unclear, an increase 
in bouton PV levels decreases the duration of Ca2+ transients that influence GABA release 
(Collin et al., 2005). Thus, an increase in PVb bouton PV levels could result in greater bouton-
specific regulation over GABA release with age. 
The distinct differences in the maturation of PVb and PVch boutons may provide insight 
into the nature or timing of the reported alterations in these types of boutons in schizophrenia. 
For example, the density of PVch cartridges detectable by GAT1 immunoreactivity is 40% lower 
in the PFC of schizophrenia subjects relative to matched comparison subjects (Woo et al., 1998; 
Pierri et al., 1999). This difference could represent an excessive developmental elimination of 
PVch boutons. In addition, lower levels of PV protein in putative PVb boutons in schizophrenia 
(Glausier et al., 2012) might represent a disease-related impairment in the normal developmental 
rise of PV levels in these boutons observed in the present study. Together, these alterations in 
perisomatic inhibitory regulation of pyramidal cell function might contribute to the emergence of 
PFC-mediated cognitive disturbances well before the clinical onset of schizophrenia during late 
adolescence or early adulthood (Reichenberg et al., 2010). 
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5.0  GENERAL DISCUSSION 
This dissertation provides evidence for understanding the timing of GABA neuron alterations 
that occur in postmortem PFC of subjects with schizophrenia, the impact of chronic cannabis use 
during adolescence on PFC GABA circuitry, and the cell type-specific nature of postnatal 
developmental changes in PV neurons. To understand timing, we investigated whether changes 
in cortical GABA-related mRNA levels in schizophrenia reflect developmental disturbances or 
chronic illness consequences; to understand impact, we explored how repeated THC exposure 
during adolescence alters GABA-related mRNA expression levels in monkey PFC; and to 
understand cell type-specific nature, we examined the maturation of PVch and PVb boutons in 
the monkey PFC. GABA-related mRNA levels did not change as a function of age or illness 
duration in subjects with schizophrenia, suggesting that chronic illness processes may not have 
substantially contributed to their expression profiles in schizophrenia (2.0). We reported changes 
in some, but not all, GABA-related mRNAs in response to repeated THC exposure during 
adolescent development (3.0). Finally, we examined cell type-specific axon terminal 
development in the PFC and found that PVch and PVb boutons have distinctive modes of 
maturation, with a decrease in number of PVch boutons per AIS and an increase in terminal 
protein levels within PVb boutons between infancy and adulthood (4.0). In the following 
discussion, I will consider these three main topics to better clarify whether schizophrenia is 
better conceptualized as a neurodevelopmental or neurodegenerative disorder (5.1), to establish 
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the impact of cannabis use during adolescence on PFC GABA neuron maturation (5.2), and to 
investigate the differences between PVch and PVb maturation in monkey PFC (5.3). I will then 
weigh the implications of this work for preemptive potential in schizophrenia (5.4). 
5.1 SCHIZOPHRENIA DISEASE COURSE: TIMING 
5.1.1 Clinical evidence for abnormal neurodevelopmental processes in schizophrenia 
Much of the evidence supporting neurodegenerative progression in schizophrenia comes from 
systematic studies of brain structure using computed tomography (CT) and magnetic resonance 
imaging (MRI) scans. CT scans showed that on average individuals with schizophrenia had 
larger lateral ventricles and cerebral sulci (Johnstone et al., 1976; Pfefferbaum et al., 1988; 
Reveley et al., 1982; Weinberger et al., 1979), and MRI scans showed widespread deficits in 
gray and white matter volumes (Shenton et al., 2001; Harvey et al., 1993; Zipursky et al., 1992). 
However, associations between illness duration and the magnitude of ventricular and gray matter 
volumes changes have not been significant (Zipursky et al., 1992; Gur et al., 1999).  
Deficits in gray and white matter and increased ventricular size in individuals with first 
episode schizophrenia are modest when compared to changes seen in different individuals with 
chronic schizophrenia (Zipursky et al., 1998; Cahn et al., 2002; Lim et al., 1996). This finding 
has been interpreted to support progressive neurodegeneration resulting from the disease; 
however, secondary factors including prolonged use of antipsychotic medications could be the 
root contributors to these cortical and ventricular alterations. In fact, recent studies have 
demonstrated a positive association between use of antipsychotics and brain volume reductions 
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using longitudinal scanning in individuals with schizophrenia beginning at their first episode of 
psychosis, with higher doses of antipsychotic medications being associated with greater 
decreases in gray and white matter volumes (Ho et al., 2011; Lieberman et al., 2005). 
Importantly, haloperidol and olanzapine led to decreases in gray and white matter volume when 
administered in monkeys and rats (Dorph-Petersen et al., 2005; Vernon et al., 2011). 
Interestingly, the withdrawal of antipsychotic administration in rats was followed by 
normalization of brain volumes on MRI scans, demonstrating a direct effect of brain volume loss 
with antipsychotic exposure (Vernon et al., 2012). Additional secondary factors associated with 
this profile of brain volume abnormalities include cannabis use, smoking cigarettes, and alcohol 
use, as well as sedentary lifestyle and high levels of stress, which are particularly relevant since 
individuals with schizophrenia have higher rates of these factors than the healthy population 
(Sapolsky, 2000; Rais et al., 2008; Mathalon et al., 2003; Stone et al., 2012; Pajonk et al., 2010). 
Together, these many factors confound the interpretation that progressive ventricular 
enlargement and cortical gray matter volume loss are due to disease-specific neurodegenerative 
processes in schizophrenia.  
One strong finding against neurodegenerative hypotheses of schizophrenia is the absence 
of classic neuropathological hallmarks such as neuronal loss, senile plaques, neurofibrillary 
tangles, and gliosis; which are all observed in neurodegenerative disorders such as Alzheimer’s 
disease, Parkinson’s disease and Huntington’s disease (Arnold et al., 1998). However, the 
absence of obvious neuropathological hallmarks does not rule out the possibility of more subtle 
disease progression and selective cell death. For example, apoptosis is responsible for neuropil 
turnover, maintenance and elimination and is not accompanied by gliosis (Bredesen et al., 2006); 
and therefore, subtle losses of neuronal subtypes due to apoptosis may have gone undetected. 
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This exception leaves open the possibility of subtle disease-related degenerative brain changes in 
schizophrenia. 
Not only have there been studies showing evidence against neurodegenerative processes 
in schizophrenia, but also observational studies have found associations between abnormal 
development and schizophrenia. For example, minor physical anomalies, such as low set ears, 
furrowed tongue, and adherent earlobes, are observed with a higher frequency in individuals 
diagnosed with schizophrenia (Green et al., 1994) and are considered to be the consequence of 
disturbed prenatal development of the ectoderm (reviewed in (Lewis and Levitt, 2002). In 
addition, clinicians were able to separately identify children who later developed schizophrenia 
from unaffected siblings, children who later developed mood disorders, and children with no 
family history of mental illness based solely on abnormal movements before 2 years of age 
(Walker et al., 1994). 
In light of these and many clinical reports, recent attempts to unify the concept of the 
etiology of schizophrenia have focused on neurodevelopmental processes. Since substantial 
refinement in human PFC circuitry was demonstrated during adolescence (Huttenlocher, 1979) 
and the age of peak clinical onset occurs during late adolescence/early adulthood (2000), one 
hypothesis put forth is that schizophrenia results from a disturbance in late developmental 
processes, such as cortical synaptic pruning during adolescence (Feinberg, 1982). Alternatively, 
the association of prenatal environmental factors with schizophrenia risk supports the hypothesis 
that schizophrenia results from a fixed brain lesion early in life that remains silent until normal 
developmental processes unmask the affected neural circuits during adolescence (Murray and 
Lewis, 1987; Weinberger, 1987). An integrated view of schizophrenia as a disorder of 
neurodevelopment states that schizophrenia results from a progressive, cumulative pathogenic 
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process that operates through adolescent development and extends through the initial phases of 
clinical illness (Keshavan et al., 1994). This integrated view is furthered by the concept of 
allostatic load, which states that the expression of diagnostic features in schizophrenia appear 
when the homeostatic system is disrupted and can longer compensate for the cumulative effects 
of genetic and environmental ‘hits’ throughout development (Thompson and Levitt, 2010; 
McEwen and Wingfield, 2003). In fact, the most recent re-conceptualization of schizophrenia 
views psychosis onset as the end stage of a protracted pathogenic process of neurodevelopment 
(Insel, 2010) (Figure 1). 
Despite recent movement towards a neurodevelopmental model of schizophrenia 
evidence exists that this may not be the only explanation, as cases exist with individuals 
experiencing clinical onset in middle or late adult life and a more rapidly deteriorating course 
(reviewed in (Church et al., 2002). However, these conflicting observations may be reconciled 
by examining subgroups of individuals diagnosed with schizophrenia or by considering that the 
breadth of the current diagnostic definition of schizophrenia may actually be a combination of 
different biological diseases. Regardless, the pathogenesis of schizophrenia appears to result in 
progressive, but initially subtle, alterations in brain circuitry without gliosis, raising the 
possibility that this progression continues throughout the lifetime course of the illness. 
(Andreasen, 2010). 
5.1.2 Molecular evidence against illness duration related changes in GABA 
neurotransmission 
In dorsolateral PFC area 9, we provide molecular evidence showing that changes in GABA-
related mRNA levels in schizophrenia are not related to illness duration and are thus unlikely to 
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result from cumulative effects of illness (Figures 8 and 9). In line with our findings, a recent 
study using a different cohort reported that declines in GAD67, GABAA α1 and GABAA α4 
mRNA levels were parallel between individuals with schizophrenia and healthy comparison 
subjects and related to age and illness duration (Duncan et al., 2010). Since age and illness 
duration were highly correlated with each other, the lack of an apparent interaction between age 
and diagnosis suggests that the parallel decline in mRNA levels across subject groups was more 
likely driven by age than illness duration. Importantly, medication status at the time of death did 
not alter the effect of age on mRNA transcript levels in the schizophrenia subject group in both 
studies. 
5.1.3 Molecular evidence for protracted development of GABA neurotransmission 
Many studies have shown that GABA neurons undergo a lengthy period of postnatal maturation 
in mammalian cortex, a period that is particularly prolonged in the monkey and human PFC 
(Erickson and Lewis, 2002; Cruz et al., 2003; Hashimoto et al., 2009; Hyde et al., 2011; Fung et 
al., 2010). Recent studies in the developing human PFC have shown that GAD67, vGAT, 
GABAA α1 and PV mRNAs all increase from birth to adolescence (Huang et al., 2007; Duncan 
et al., 2010; Fung et al., 2011b; Hyde et al., 2011; Fung et al., 2010). These findings strengthen 
our approach of using rhesus monkey PFC as a developmental model of GABA-related marker 
expression since all four markers show a similar temporal pattern as those observed in human 
PFC (Figures 10 and 11). 
In our studies, the largest changes in mRNA levels occurred between the perinatal and 
childhood periods. However, GAD65 and GABAA α1 mRNA levels increased through 
adolescence, suggesting that multiple sensitive periods of GABA neuron development may exist. 
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These multiple sensitive periods can arise since diverse aspects of cortical GABA circuitry have 
different inflection points during development, and as a consequence may be vulnerable to 
unique environmental exposures (Le Magueresse and Monyer, 2013). These findings support the 
Keshavan integrated hypothesis and the concept of allostatic load in schizophrenia, where a 
series of pathogenic processes during development culminate in the clinical onset of 
schizophrenia during late adolescence when neural circuits can no longer compensate (Keshavan 
et al., 1994; Thompson and Levitt, 2010; McEwen and Wingfield, 2003). 
5.1.4 GABA neuron mRNA expression profile in schizophrenia may reflect disruptions 
earlier in development 
Although it is not feasible to directly study postnatal developmental mRNA levels in 
schizophrenia, studies of postmortem human and monkey tissue have suggested that alterations 
in PFC GABA-related mRNA levels may result from an earlier disruption in the expression 
trajectories of these markers. For example, lower GAD67 mRNA levels were found in PFC 
tissue from schizophrenia subjects (Akbarian et al., 1995b; Guidotti et al., 2000; Curley et al., 
2011; Hashimoto et al., 2008a; Volk et al., 2000; Duncan et al., 2010), along with a parallel age-
related decline in GAD67 mRNA levels between schizophrenia and comparison subject groups 
(Duncan et al., 2010) and with no significant effect of illness duration on these levels (Figures 8 
and 9), suggesting that alterations in GAD67 mRNA levels occurred during development before 
clinical onset. In addition, two independent studies have shown that GAD67 mRNA levels 
increase substantially from birth into late childhood/early adolescence in human PFC tissue 
(Huang et al., 2007; Hyde et al., 2011), a finding paralleled in our studies in monkey PFC 
(Figure 10). Together these findings provide support for the idea that lower GAD67 mRNA 
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levels in the PFC of subjects with schizophrenia may reflect disturbances in their dynamic 
developmental expression trajectories. 
We also found similar patterns of lowered mRNA levels in other GABA-related profiles, 
such as vGAT, GABAA α1 and PV in schizophrenia, which all have increasing postnatal mRNA 
levels (Figures 10 and 11), supporting the hypothesis that these disturbances in schizophrenia 
may result from disrupted postnatal development. Additional support comes from investigating 
GABAA α2, the GABAA δ subunit, which is involved in tonic inhibition (Drake and Milner, 
2002; Stumm et al., 2004; Farrant and Nusser, 2005), and the µ-opioid receptor (MOR), which 
suppresses GABA release when activated (Drasbek et al., 2007; Drasbek and Jensen, 2006). In 
PFC tissue from schizophrenia subjects, levels of GABAA α2 and MOR mRNAs were higher and 
GABAA δ mRNAs were lower, and each transcript had an inverse developmental expression 
trajectory (Maldonado-Aviles et al., 2009; Beneyto et al., 2011; Hashimoto et al., 2009; Volk et 
al., 2012b). 
Cortical transcripts other than GABA-related mRNAs may also be developmentally 
disrupted. For example, mRNA levels of the metabotropic glutamate receptor subunit 1α 
(mGluR1α) and the regulator of G-protein signaling (RGS4) were higher and lower, respectively, 
in schizophrenia (Volk et al., 2010), while their postnatal developmental trajectories were 
opposite in direction with mGluR1α decreasing and RGS4 increasing in monkey PFC (Volk 
DW, Personal Communication). In mice, a postnatal developmental increase in the NMDA 
receptor subunits GluN1 and GluN2A occurs, and this finding for GluN1 has been replicated in 
human PFC. Interestingly, GluN1 and GluN2A mRNA levels were recently reported lower in 
subjects with schizophrenia (Beneyto and Meador-Woodruff, 2006). Thus, in postmortem PFC 
tissue from schizophrenia subjects, multiple transcripts that regulate neuronal excitability appear 
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to have patterns of altered expression that may reflect an underlying disruption in postnatal 
development. 
The combination of findings discussed above supports the hypothesis that the normal 
development of PFC GABA neurons is disrupted in schizophrenia and may, at least in part, 
underlie cognitive dysfunction in the illness. Recently, a longitudinal, prospective cohort study 
examined the development of cognitive function in children who later developed schizophrenia 
compared to those who remained healthy (Reichenberg et al., 2010), advancing three hypotheses 
(Figure 18): 1) Developmental lag, which predicts growth of cognitive function but at a slower 
rate than the growth seen in healthy individuals; 2) Developmental deficit, which predicts static 
cognitive impairment early in development; and 3) Developmental deterioration, which predicts 
a premorbid decline in cognitive functioning. In that study, the developmental lag model best 
predicted differences in working memory performance between the two subject groups. These 
findings support the possibility that the PFC neural circuits underlying working memory ability, 
which includes GABA neurons, undergo pathological alterations during childhood well before 
the onset of psychosis. Indeed, a variety of environmental insults that accumulate during 
childhood and adolescence may mitigate both developmental disruptions in cognitive 
development and in underlying GABA circuitry. Interestingly, a number of recent 
epidemiological studies suggest that cognitive deficits in schizophrenia subjects do not decline in 
excess of normal aging and there is no evidence of obvious neurodegeneration in excess of what 
is seen during normal aging (Rajji et al., 2012; Harvey et al., 2006). These findings together with 
the absence of cell density changes in the PFC of schizophrenia subjects (reviewed in (Lewis and 
Gonzalez-Burgos, 2008) suggest that alterations may occur earlier in development. The 
implications of understanding timing in schizophrenia will be discussed in (5.4). 
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Figure 18. Hypotheses of premorbid cognitive development in schizophrenia 
Left panel shows a developmental lag, where the rate of improvement in cognitive function is slower in 
schizophrenia subjects; center panel shows a static deficit from an early age in schizophrenia subjects; and right 
panel shows a deterioration of cognitive function in schizophrenia subjects. Adapted from Reichenberg et al., 2010. 
5.1.5 Future direction 
In sections 5.1.1-5.1.4, I have argued that schizophrenia can be viewed as a neurodevelopmental 
disorder and that the timing of neural circuit changes during development is critical to study in 
detail. One mechanistic approach for examining the effects of a developmental disruption on the 
maturation of GABA neurons is to manipulate interneuron specific transcription factors during 
different developmental time periods. For example, Lhx6, which is a LIM homeodomain 
transcription factor, regulates the development of PV and SST neurons during prenatal migration 
to the cerebral cortex (Xu et al., 2004; Butt et al., 2005; Cobos et al., 2006) and throughout 
adulthood in a cell type-specific manner (Jakovcevski et al., 2011). In Lhx6 germline allelic 
deletion mice (Lhx6—), both the tangential migration to the cortex and radial migration within 
the cortical plate appeared to be disturbed (Zhao et al., 2008; Liodis et al., 2007), resulting in the 
abnormal distribution of GABA neurons. Lhx6— animals also had a reduction in the density of 
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PV and SST neurons (Zhao et al., 2008; Liodis et al., 2007), indicating the importance of Lhx6 
for their differentiation. In PFC tissue from subjects with schizophrenia, Lhx6 mRNA levels 
were lower (Volk et al., 2012a), and in a subset of these individuals, lower Lhx6 mRNA levels 
were accompanied by lower GAD67, PV and SST mRNA levels (Volk et al., 2012a). These 
findings suggest that alterations in Lhx6 expression may affect the development or maintenance 
of the PV and SST phenotype in this subset of individuals with schizophrenia.  
To determine the effects of a cell type-specific perturbation on PFC cortical circuit 
maturation, a conditional Lhx6 disruption using a cre-lox reporter system in rodent organotypic 
slice cultures during different stages of development can be used (Liodis et al., 2007; Neves et 
al., 2012; Chattopadhyaya et al., 2007). A recent study used homologous recombination in 
embryonic stem cells to generate a mutant allele of Lhx6, where exons encoding the functional 
domain were deleted and replaced with an IRES-GFP reporter cassette. Animals heterozygous 
for the Lhx6— mutation were generated and characterized, but Lhx6— homozygous mutants died 
during the first two weeks after birth. To create the conditional knockout, mice that have a floxed 
Lhx6 mutant allele can be generated and organotypic slice cultures from these animals can be 
transfected with a cre-recombinase and GFP-cassette under the GAD67 promoter 
(Chattopadhyaya et al., 2004; Chattopadhyaya et al., 2007). Transfection of the GAD67 
promoter cassette during different stages of slice development can be used to study its effects on 
markers of cortical GABA transmission, and a number of predictions can be made based on the 
timing of this manipulation. For example, perinatal disruption of Lhx6 may result in abnormal 
neural migration lower densities of PFC GABA neurons, as observed in other brain regions 
(Liodis et al., 2007; Zhao et al., 2008). However, disruption during the equivalent postnatal 
adolescent period in rodent organotypic culture might alter GABA-related mRNA levels without 
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a change in cell density, since postnatal Lhx6 levels are important for the expression of PV and 
SST phenotypes. Importantly, this manipulation allows us to measure the developmental 
trajectories of pre and postsynaptic GABA-related markers. 
5.2 IMPACT OF ADOLESCENT CANNABIS USE ON PFC GABA NEURONS 
As shown in Figure 12, GAD65 mRNA levels were higher and PV mRNA levels were lower in 
the PFC from THC-treated postpubertal monkeys relative to behaviorally matched, vehicle-
treated comparison subjects. However GAD67, CB1R and CCK mRNA levels did not differ 
between groups. These findings suggest that selective alterations in markers of cortical GABA 
neurotransmission occur in response to chronic THC administration during adolescence. 
5.2.1 THC-mediated endocannabinoid signaling alterations 
Phasic endocannabinoid signaling acts “on-demand” in a synapse-specific fashion such 
that endocannabinoids are released when they are needed (Marsicano et al., 2003) and their 
effect of suppressing neurotransmitter release is restricted to the associated presynaptic site 
(Brown et al., 2003) (Figure 19). Since CB1R are much more highly concentrated at 
GABAergic CCKb terminals than at glutamatergic terminals (Kawamura et al., 2006; 
Uchigashima et al., 2007), they are assumed to be more influential at CCKb terminals. However, 
a recent study in mouse hippocampus found that the minority of glutamatergic CB1R are 
paradoxically several fold more strongly coupled to G-protein signaling than GABAergic CB1R 
(Steindel et al., 2013). Interestingly, the enzyme that synthesizes 2-AG, which is a critical 
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mediator of DSI and DSE, was present at higher amounts in neocortical glutamate synapses 
relative to GABA synapses (Katona and Freund, 2012). GABAergic CB1R were also not 
involved in seizure susceptibility (Monory et al., 2006); however, they did appear to be critical 
for mediating THC-induced long-term memory deficits (Puighermanal et al., 2009) and for 
protecting against age-related cognitive decline (Albayram et al., 2011). Together, these 
properties have led to the hypotheses that the endocannabinoid system acts as a glutamatergic 
and GABAergic circuit breaker (Katona and Freund, 2012). However, THC exposure abolishes 
the “on-demand” synapse-specific nature of endocannabinoid signaling, and may alter the 
delicate balance between excitation and inhibition due to its “blanket of CB1R activation” at 
glutamate and GABA synapses.  
Two cellular mechanisms by which THC administration may disrupt PV neuron 
maturation could involve phasic and/or tonic endocannabinoid signaling alterations in different 
inputs to PV neurons (Figure 20). In one example, THC induces DSI at CCKb inputs to PVb and 
pyramidal neurons. An acute break in inhibition may serve to increase excitability in PVb and 
pyramidal neurons. In this scenario, the perisomatic GABAergic network may be imbalanced 
such that the contribution of PVb inputs becomes too large and the contribution of CCKb too 
small. Given that PV neurons appear to be critical time keepers and CCKb neurons appear to be 
integrators of information from different cortical and subcortical areas, one possibility is that  
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Figure 19. Synapse specific effect of endocannabinoid signaling 
(A) Precise “on-demand” nature of endocannabinoid signaling. Upper pyramidal (P) cell is depolarized as indicated 
by (+), leading to the production and release of 2-AG which suppresses GABA release form a CCKb (purple 
neuron) terminal via CB1R activation. Lower pyramidal cell is quiescent resulting in normal levels of GABA release 
from the same CCKb neuron. (B) Proposed effect of THC, which abolishes the synapse-specific nature of 
endocannabinoid signaling by activating CB1R at all synapses regardless of the membrane polarization state of the 
postsynaptic neuron. 
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Figure 20. Potential effects of THC on PFC neural activity 
THC-induced alterations of inputs to PVb neurons may disrupt adolescent PV neuron maturation. (1) DSI is 
depicted as occurring at GABA terminals from CCKb apposed to PVb and pyramidal (P) neurons. However, 
whether the same CCKb targets both PVb and pyramidal neurons is unknown. (2) DSE is shown to occur either 
directly at inputs to PVb neurons, or indirectly at glutamate inputs to other pyramidal neurons that also innervate 
PVb. Question marks indicate that the CB1R localization on glutamate inputs is unknown, especially in the primate 
PFC, and it is unclear what the functional impact of chronic CB1R activation on PFC neural circuit activity may be 
in response to THC.  
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excessive amounts of THC during adolescence upsets the balance between “rhythm” and “mood” 
(Freund, 2003; Freund and Katona, 2007). Alterations in DSE can potentially affect excitatory 
inputs to PVb neurons. For example, competition between direct (pyramidal inputs to PVb) and 
indirect (pyramidal to pyramidal to PVb) reductions in glutamate release from pyramidal cell 
axon terminals to PVb could also influence network excitability and potentially alter the 
normally precisely sculpted modulation of glutamate release from these axon terminals (Figure 
20). If CB1R become functionally uncoupled from their G-protein signaling pathways (Katona 
and Freund, 2012), then the mechanisms of protection from excitotoxicity or excessive inhibition 
may no longer properly function when needed. Thus, a reduction in excitatory drive of PVb 
neurons may lead to a reduction of PV expression, since it is linked with cell activity (Heizmann, 
1984). In contrast, a decline in GABA release from CCKb may result in a reduction of GAD65 
protein levels and subsequent compensatory response that increases GAD65 mRNA levels. 
The consequences of chronic THC exposure on tonic endocannabinoid signaling must 
also be considered as a possible mechanism, since the ambient amount of extracellular 
cannabinoid concentration has been recently shown to affect the release of neurotransmission 
(Katona and Freund, 2012). For example, paired recordings in rodent hippocampus showed that 
tonic endocannabinoid signaling can suppress GABA release in a CB1R-dependent manner 
(Losonczy et al., 2004). The persistence of elevated THC levels may alter the tone of 
endocannabinoid signaling by reducing terminal CB1R density or uncoupling CB1R from their 
G-protein signaling pathways (Katona and Freund, 2012). These changes raise the possibility 
that CCKb terminals (and possibly glutamate terminals) would no longer be sensitive to 
endocannabinoids released from the depolarized postsynaptic cell. Therefore, the precise “break 
in inhibition” mechanism would be lost and output from the postsynaptic cell would likely be 
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altered. Consequently, alterations in CCKb and pyramidal cell inputs to PVb during sensitive 
periods of postnatal development could disrupt the normal maturation of PVb neurons. 
5.2.2 Implications for schizophrenia 
Recent behavioral studies in the same monkeys used in 3.0 showed that repeated THC exposure 
during adolescence led to residual impairments in spatial working memory processes that 
persisted during the period of exposure and did not produce tolerance to the acute impairing 
cognitive effects of THC (Verrico et al., American Journal of Psychiatry, In Revision). We 
reported evidence of molecular changes in dorsolateral PFC GABA circuitry from these 
monkeys. Together, these findings raise concerns that cannabis use during adolescence may 
result in poorer academic performance (Fergusson and Boden, 2008; Lynskey and Hall, 2000; 
Harvey et al., 2007) by potentially interfering with normal maturation of PFC neural circuits. 
Moreover, cannabis use in individuals with a predisposition for developing schizophrenia may 
impact PFC circuitry in such a way that increases the likelihood, and accelerates the onset, of 
psychosis (Henquet et al., 2005a; Large et al., 2011; Moore et al., 2007; Veen et al., 2004). 
5.2.3 Future Direction 
The impacts of these many changes in response to chronic THC are currently unclear; however, 
one plausible approach to disentangling the effects of THC on glutamatergic and GABAergic 
inputs is to conduct a dose-response study in conditional glutamatergic and GABAergic CB1R 
knockout mice (Monory et al., 2006) using THC and measure its effect on DSI, DSE, and tonic 
endocannabinoid signaling. A study in these conditional knockout animals that would measure 
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the trajectories of GABA-related mRNA level expression in the mouse medial PFC, which is 
thought to be the mouse homologue of the primate dorsolateral PFC, is also of great interest in 
order to better understand the effects of THC at glutamate or GABA terminals on GABA neuron 
maturation. Whether these molecular findings in rodents apply to the primate PFC is currently 
unclear and warrants further study. 
The long period of maturation of PV neural inputs to pyramidal cells provides many 
opportunities, as well as cell type-specific targets, for the effects of perturbations to be amplified 
as they alter the trajectories of the developmental events that follow. Indeed during the same 
period, monkeys and humans undergo substantial improvements in emotion regulation and 
cognitive control. The temporal overlap of the opposing developmental changes in PVch and 
PVb boutons may provide the opportunity for a single environmental risk factor for 
schizophrenia (i.e. cannabis use during adolescence) to disrupt the maturation of both PV 
terminal subtypes. In a future study, we plan to measure both the density of PVb, PVch, and 
CCKb boutons and relative levels of GAD67, GAD65, PV and CB1R protein within these 
bouton populations in the same adolescent, THC-treated animals (3.0) using a multiple label, 
confocal immunofluorescence microscopy and image segmentation approach (4.0). Given the 
terminal specific expression of GAD67, GAD65, PV and CB1R protein, we can discriminate 
among the three terminal populations described above as follows: PVb boutons would consist of 
GAD65/PV fluorescence overlap; PVch boutons would consist of GAD67/PV overlap; and 
CB1R would have GAD65/CB1R overlap. Therefore, in this study, we will be able to measure 
bouton-specific levels of GAD, PV and CB1R in response to chronic adolescent THC exposure. 
We will also be able to measure the comparative densities of these three bouton populations 
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across experimental and control groups. This future study could provide evidence that chronic 
THC exposure during adolescence affects PVch and PVb bouton maturation. 
5.3 PV-CONTAINING CHANDELIER AND BASKET CELL BOUTONS IN THE 
PFC: CELL TYPE-SPECIFIC POSTNATAL DEVELOPMENT  
In 4.0, we reported that the number of PVch boutons per AIS declined between 3 months and 
adulthood in monkey PFC, but that relative vGAT and PV protein levels per PVch bouton and 
levels of adjacent γ2 receptor clusters at AIS did not differ between these two age groups. Since 
the detectability of two proteins involved in GABA transmission per PVch bouton and the 
adjacent postsynaptic receptor clusters did not change, these findings suggest that PVch boutons 
were pruned between infancy and adulthood in monkey PFC. 
5.3.1 PVch structural plasticity – More than loss, possible rearrangement 
The substantial loss of PVch boutons per AIS was accompanied by a similar magnitude decrease 
in AIS length, resulting in a stable density of PVch boutons per AIS in both 3 mo and adult 
animals. In order to determine if the reduction in AIS length altered the distribution of PVch 
boutons in adult animals despite no change in PVch bouton density, the data were binned into 3 
groups representing the proximal, middle, and distal thirds of the total AIS length relative to the 
axon hillock. The distribution of boutons differed across age groups (Χ2 [2] = 30.5, P < 0.001) 
(Figure 21). In the 3 mo monkeys, the proportions of PVch boutons significantly differed (F2,6 = 
8.49, P = 0.018) between the proximal (31.5%) middle (36.8%), and distal (31.7%) portions of 
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the AIS. Post-hoc tests found a significant difference in the middle region compared to both the 
proximal and distal regions (P = 0.025 and 0.03, respectively). In adult monkeys, the proportions 
of PVch boutons significantly differed (F2,6 = 48.6, P < 0.001) between the proximal (35.4%) 
middle (34.8%), and distal (29.8%) portions of the AIS. Post-hoc tests found a significant 
difference in the distal region compared to both the middle and proximal regions (P < 0.001, for 
both). The difference in PVch distribution between 3 mo and adult monkeys suggests that these 
connections are significantly rearranged between these time points. 
 
 
Figure 21. PVch distribution along the AIS differs between 3 mo and adult animals 
Representative images of NeuN-IR somata and AnkG-IR AIS from 3 mo (left) and adult (right) animals. Values 
represent the mean percentage of PVch boutons per third along the AIS for each age group. Asterisks denote the 
axon hillock. Scale bar, 10 μm. 
 
Previous studies have indicated that PVch boutons can be differentially distributed along 
AIS (DeFelipe and Farinas, 1992), and that AIS are highly plastic structures (reviewed in (Grubb 
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et al., 2011). These reports were made in regions and in species other than the adult monkey 
(DeFelipe et al., 1985; Farinas and DeFelipe, 1991; Jones and Powell, 1969; Freund et al., 1983). 
In addition, recent studies have found that the distribution of the AnkG compartment within AIS 
varies as a function of neuronal activity (reviewed in (Grubb et al., 2011). Interestingly, 
removing input by unilateral cochlear ablation increased the AnkG AIS length by 1.7-fold and 
increased voltage gated sodium channel clustering (Kuba et al., 2010). In contrast, increasing the 
excitatory drive in rodent dissociated hippocampal neuronal cultures using extracellular KCl or 
by evoking AP burst firing using optogenetics did not alter AIS length as measured by AnkG 
immunoreactivity, but shifted the entire structure 17 μm away from the soma (Grubb and 
Burrone, 2010). At the molecular level, AnkG is critical for concentrating a number of structural 
components at the AIS including the cell adhesion molecule, neurofascin 186 (Hedstrom et al., 
2007). Recent evidence suggests that the neurofascin 186 gradient is critical for the proper 
targeting of GABA synapses to the AIS (Ango et al., 2004). Recent studies indicate that 
alterations in AIS length may occur in vivo (Baalman et al., 2013; Hinman et al., 2013). For 
example, cortical and hippocampal AIS were significantly shorter in rats exposed to a single 
blast wave that induced mild traumatic brain injury and behavior phenotypes (Baalman et al., 
2013). In concert, an activity-dependent shift in AnkG may alter the distribution of neurofascin 
186 such that PVch boutons redistribute between 3 months and adulthood. 
5.3.2 PFC activity as a driving force for PVch and PVb bouton maturation 
The mechanisms by which these distinctive modes of maturation in PVch and PVb boutons 
occur may ultimately depend upon PFC neural activity. For example, as discussed in the 
previous section, a loss of PVch boutons may occur in response to AIS reorganization. Longer 
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AnkG-labeled AIS during early postnatal development could provide an initial large target for 
stochastic innervations by pathfinding PVch axons. Once innervated and in response to changes 
in PFC network activity during postnatal development, AIS would be refined, potentially along 
with the PVch terminals that innervate them. Shortening of AIS both in response to increase 
neural activity and during postnatal development has been shown in slice preparations in vitro 
(Kuba et al., 2010). However, the developmental dynamics of PVch boutons and AnkG-
immunoreactivity at the same AIS have not been studied. 
 The functional impact of changes in PVch innervation of pyramidal cell AIS will depend 
upon a number of factors, including understanding the effect of GABA release on AIS 
membrane polarization. Recent studies have found that PVch are depolarizing and can even be 
excitatory under certain conditions in certain brain regions (Woodruff et al., 2009; Woodruff et 
al., 2011; Szabadics et al., 2006). Another study reported that PVch tonically inhibited the AIS 
and blocked back-propagating action currents during induced rhythmic activity in vitro 
(Dugladze et al., 2012). Thus, detailed studies on the state- and region-dependent effects of PVch 
GABA transmission on pyramidal neuron activity are critical for understanding the dynamic 
structural changes observed in our studies. 
While PVb boutons do not appear to be pruned like PVch, they undergo functional 
maturation between 3 months and adulthood in monkey PFC. We observed increases in the 
relative protein levels of vGAT and PV in PVb boutons (Table 1) without a corresponding 
change in the density of these boutons in the neuropil. Increases in these proteins may indicate an 
altered capacity for the regulation of GABA neurotransmission, since vGAT loads GABA into 
presynaptic vesicles (Chaudhry et al., 1998) and PV regulates intracellular Ca2+ dynamics 
(Eggermann and Jonas, 2012). Increases in PV neural activity during postnatal development may 
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drive the increases in PV protein levels within PVb boutons, since changes in PV content have 
been reported to be associated with corresponding increases or decreases in neuronal activity 
(Heizmann, 1984). The lack of change in PV and vGAT protein levels within PVch between 3 
months and adulthood may indicate that PVch boutons have already undergone increases in these 
proteins before 3 months of age. 
5.3.3 Implications for schizophrenia 
PVch cells currently represent the only known pathological entity in schizophrenia to have 
alterations in both pre and postsynaptic protein components. In light of our findings, the robust 
40% reduction in the detectability of GAT1-IR cartridges in the PFC of schizophrenia subjects 
(Pierri et al, 1999) may reflect a structural loss of PVch boutons. Whether a structural loss of 
PVch boutons or a reduction of GAT1 protein levels per intact PVch bouton occurs in 
schizophrenia has potential implications for therapeutic intervention. For example, if presynaptic 
PVch can no longer release enough GABA when required, then allosteric modulators of GABAA 
α2 may help boost the effect of the limited amount of GABA released by keeping the 
postsynaptic receptors open for a longer period of time, but only when GABA is bound to the 
receptor. In contrast, if the presynaptic PVch structure is no longer present, then such an 
allosteric modulator would be ineffective, assuming that no tangible amounts of GABA would be 
synaptically present when needed. Recent studies found that a novel compound that enhances 
GABA transmission at GABAA α2-containing receptors was associated with working memory 
functional improvement in subjects with schizophrenia (Lewis et al., 2008) and in an animal 
model of cognitive deficits of schizophrenia (Castner et al., 2010). In contrast, a larger clinical 
study in chronically ill subjects with schizophrenia showed little benefit (Buchanan et al., 2011). 
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Still, the possibility that this kind of intervention could be beneficial earlier in the illness, and 
possibly before psychosis onset, remains to be determined (Lewis, 2012). 
Similar to the contrast between PVch and PVb during postnatal development, PVb 
boutons appear to have reduced levels of PV protein, without a change in bouton density in the 
PFC of subjects with schizophrenia (Glausier et al, Molecular Psychiatry, In Revision). These 
findings may reflect reduction in PFC network activity in schizophrenia, and ultimately may 
require interventions that alter network excitability either by boosting excitation or dampening 
inhibition. 
5.3.4 Future direction 
Studying the cell type-specific maturation of PV neurons is of special interest in the context of 
understanding how these findings may inform on the pathogenesis of schizophrenia. In this 
regard, it would be interesting to pursue a multiple label, confocal immunofluorescence 
microscopy study in postmortem human PFC from subjects with schizophrenia. Given our 
developmental findings, testing whether PVch bouton number per AIS is lower without a change 
in PVb bouton density in the same subjects with schizophrenia would provide valuable 
information at the terminal specific level. We have been able to robustly image GAD67, GAD65, 
PV, GAT1, βIV spectrin, an AIS marker similar to AnkG; and GABAA α1 and γ2 in postmortem 
human tissue (Fish KN, Personal Communication). Therefore, multiple label confocal 
immunofluorescence microscopy studies examining PVch and PVb are feasible in schizophrenia 
and comparison subjects.  
Given the time-limited nature of sensitive periods during development, studying more 
time points during postnatal development is important for determining more precisely when 
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these changes in PVch and PVb occur. Thus, the more precise timing of PVch bouton loss and 
PV protein level increases in PVb are the foci of ongoing investigations. We are currently 
examining the same measures as presented in 4.0 during the perinatal period (1 week and 1 
month of age) and during adolescence (18 and 45 months of age). 
5.4 PREEMPTIVE POTENTIAL IN SCHIZOPHRENIA 
The studies presented in this dissertation ultimately aim to provide information that could be 
critical for advancing preemptive and preventive strategies during preclinical illness progression 
or for reducing preclinical risk for schizophrenia. 
5.4.1 Timing of intervention 
Since the appearance of the diagnostic clinical features of schizophrenia is believed to represent 
a late, and potentially preventable, outcome of the illness, the development of effective 
preemptive treatments requires knowledge of neural circuit abnormalities that underlie the 
central features of the illness, when during the course of development these abnormalities arise, 
and how to detect these abnormalities before their functional impact becomes clinical (Insel, 
2010; Lewis, 2012 ). 
Whether key pathological events in schizophrenia occur during the perinatal period, 
adolescence, or some other period depending on the individual will determine when to intervene. 
These interventions may require pharmacological approaches to target and rescue molecular 
pathways that may be upstream of the inhibitory deficit in schizophrenia or that may modulate 
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GABA neurotransmission. For example, PFC GABA inhibition may be reduced in schizophrenia 
as a compensation for an upstream reduction in excitation (Lewis et al., 2012). In this case, 
interventions might need to be delivered early in life and target molecular pathways that regulate 
spine formation. Alternatively, in some cases, a primary deficit in specific GABA neurons may 
underlie the pathogenesis of schizophrenia. In line with this possibility, allelic variation in GAD1 
has been associated with schizophrenia (Straub et al., 2007). Given that Lhx6 expression deficits 
are associated with deficits in GAD67 and PV in some individuals with schizophrenia, 
intervening by boosting Lhx6 levels during early development may rescue some of the 
phenotypic alterations in PV neurons in schizophrenia. It is possible that targeting both 
excitatory pathways and boosting GABA neurotransmission could have synergistic effects on 
restoring circuit function in schizophrenia. Importantly, understanding the normal maturation of 
PFC circuitry may also provide information about when interventions should be held for safety. 
As previously discussed, cannabis use before the age of 16 years has been reported to 
increase the risk for, and decrease the age of onset of, schizophrenia in a dose-dependent manner 
(Moore et al., 2007). In fact, a recent meta-analysis estimated that about 14% of schizophrenia 
cases would not occur without cannabis consumption (Moore et al., 2007). Interestingly, a recent 
questionnaire that measured subclinical psychotic experiences found that individuals without any 
evidence of a predisposition for schizophrenia responded to cannabis by feeling more at ease 
with the world, while those who had reported previous subclinical psychotic experiences has 
increased feelings of suspicion and hostility as well as marked perceptual changes (Verdoux et 
al., 2003; Konings and Maharajh, 2006). Therefore, public health measures aimed at individuals 
at risk for psychosis and designed to reduce or delay the use of cannabis during the early teenage 
years may help substantially reduce the appearance of psychosis in schizophrenia. 
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In those individuals who are at risk and consistently use cannabis during adolescence, 
interventions during adolescence or in early adulthood may ameliorate some of the circuit 
alterations. For example, allosteric modulators of different types of g-protein coupled receptors 
whose signaling cascade results in the release of endocannabinoids can be used to alter levels of 
these cannabinoids (Porter and Felder, 2001). In addition, a number of cannabinoids that can 
modulate the effect of THC exist, and detailed studies of these compounds and their effects on 
cannabinoid signaling, the appropriate dosage, route of administration, and timing of intervention 
need to be studied (Croxford, 2003) prior to understanding whether manipulation of this system 
will be therapeutic in schizophrenia. 
5.4.2 Harnessing neural plasticity 
The association of multiple genetic and environmental risk factors for schizophrenia well before 
the clinical onset of diagnostic features may lead to the grim conclusion that individuals who 
begin with high risk are on an irreversible path to developing the illness. In this view, 
development is an especially vulnerable period to insults that can result in the emergence of 
significant pathology later in life. For example, metabolic disorders like phenylketonuria can 
lead to profound and irreversible cognitive disability when left uncorrected during development, 
but in adults they seem to have milder effects (Hanley, 2004). However, there are examples of 
other pathologies like trauma or infection that have milder effects during development than in 
adults (Kolb et al., 2000). One remarkable example of the human brain’s ability to adapt occurs 
in young children who undergo functional hemispherectomy as a result of intractable seizures, a 
damaged hemicortex and hemiplegia. In many of these individuals, not only do they recover 
from seizures, but also they can improve in cognitive and motor functioning (Wiebe and Berg, 
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2013). These examples support the alternative view that individuals with neurodevelopmental 
disorders like schizophrenia are not necessarily “doomed from the womb.” 
Harnessing adult neural plasticity to compensate for or possibly correct specific 
pathologies may be a viable way to conceptualize future treatment strategies for schizophrenia. 
Certain genes known to be critical for normal pre and postnatal neurodevelopment and possibly 
disrupted during those periods [i.e. DISC1, NRG1 (Jaaro-Peled et al., 2009)], and notably Lhx6, 
are also expressed in the adult brain. Ongoing disruptions in the expression of these genes during 
adulthood may contribute to cognitive dysfunction in schizophrenia. Thus, adult rescue of 
molecules that are critical during development but also function in adulthood may help alleviate 
or correct disruptions that begin during development. Recent studies suggest that the adult rodent 
cortex remains plastic, with the ability to produce structural changes in dendritic spines 
(Trachtenberg et al., 2002), axons (Florence et al., 1998) and dendrites (Tailby et al., 2005). In 
rodents, substantial plasticity can occur beyond the developmental critical period in the 
somatosensory and visual cortices (Buonomano and Merzenich, 1998; Sawtell et al., 2003). 
Again, whether these findings in rodents apply to the primate PFC is an open question that 
remains to be studied. 
A more promising option may be to alter pathological plasticity as it occurs during 
sensitive periods of development. This approach may have a higher impact since the mechanisms 
of plasticity during sensitive periods appear to differ from those in adulthood. For example, 
dendritic spine motility decreases beyond the critical period (Holtmaat et al., 2005) and 
thalamocortical axon plasticity and long term potentiation are reduced or eliminated (Crair and 
Malenka, 1995; Hubel and Freeman, 1977). In rodents, the critical period window for ocular 
dominance plasticity can be manipulated by altering levels of cortical inhibition (Fagiolini and 
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Hensch, 2000; Hensch, 2005; Hensch et al., 1998; Huang et al., 1999). Recent findings suggest 
that PV inputs to GABAA α1 containing receptor clusters are crucial for setting the timing of this 
critical period window (Fagiolini et al., 2004) and thus may represent both a locus of cellular 
vulnerability and a potential therapeutic target. Another recent study showed that GABAA α1 
number decreased in the soma-proximal dendrite compartment, but not on the AIS with age and 
sensory deprivation. Interestingly, the number of soma-proximal dendrite GABAA α1 in 
immature or dark-reared mice were adjusted to critical period levels by in vivo benzodiazepine 
treatment, triggering ocular dominance plasticity in these animals (Katagiri et al., 2007). Using a 
GAD65 knockout animal model and subsequent rescue the critical period onset with dark-rearing 
in these animals, they found that an intermediate number of PV to GABAA α1 connections is 
required to trigger the critical period. These findings raise implications that in schizophrenia, the 
appropriate trigger for sensitive periods of development may be delayed or accelerated, since 
perisomatic PV inputs to GABAA α1 clusters appear to be altered in the disorder. The potential 
for manipulating the onset of sensitive periods in PFC circuits holds promise as a novel 
therapeutic intervention; however, determining the precise timing and nature of the onset of PFC 
sensitive periods is required first. 
5.5 CONCLUDING REMARKS 
This dissertation explored the postnatal development of PFC GABA neurons with the goals of 
identifying periods of vulnerability to schizophrenia, the impact of an environmental insult on 
developing PFC GABA neurons, and the cell type-specific maturation of PFC GABA neuron 
axon terminals. We found gene expression changes in key functional markers of GABA 
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neurotransmission during the perinatal and adolescent periods of development (2.0), periods of 
development that are associated with a variety of risk factors for schizophrenia. The mRNA 
levels for these same markers did not change as a function of age or illness duration in subjects 
with schizophrenia, suggesting that chronic illness processes may not have substantially 
contributed to their expression profiles in schizophrenia. Since environmental factors are known 
to affect developing neural systems and contribute to the etiology of schizophrenia, we studied 
the impact of chronic THC administration on markers of PFC GABA neurotransmission during 
adolescence in monkeys. We reported changes in some, but not all, GABA-related mRNAs 
suggesting that repeated THC exposure selectively alters PFC GABA neurons during adolescent 
development (3.0). Finally, we examined cell type-specific axon terminal development in the 
PFC and found that PVch and PVb boutons have distinctive modes of maturation, with a 
decrease in number of PVch boutons per AIS and an increase in terminal protein levels within 
PVb boutons between infancy and adulthood (4.0). Each of these findings highlights the 
dynamic, “double-edged sword” of postnatal PFC development, which may not only open 
windows of susceptibility to pathological insults, but also windows of adaptability to 
pathological alterations in schizophrenia. 
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APPENDIX A 
A.1 DEMOGRAPHIC, POSTMORTEM, AND CLINICAL CHARACTERISTICS OF HUMAN SUBJECTS USED IN THIS 
DISSERTATION 
Table 6. Human subjects used in this dissertation. 
Healthy Comparison Subjects 
Pair Case Sex/ Race Age PMI
a Storage Timeb RIN pH Cause of Death 
1 592 M/B 41 22.1 174 9.0 6.7 ASCVD 
2 567 F/W 46 15.0 178 8.9 6.7 Mitral valve prolapse 
3 516 M/B 20 14.0 185 8.4 6.9 Homicide by gun shot 
4 630 M/W 65 21.2 168 9.0 7.0 ASCVD 
5 604 M/W 39 19.3 172 8.6 7.1 Hypoplastic coronary artery 
6 546 F/W 37 23.5 182 8.6 6.7 ASCVD 
7 551 M/W 61 16.4 181 8.3 6.6 Cardiac tamponade 
8 685 M/W 56 14.5 161 8.1 6.6 Hypoplastic coronary artery 
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9 681 M/W 51 11.6 162 8.9 7.2 Hypertrophic cardio-myopathy 
10 806 M/W 57 24.0 141 7.8 6.9 Pulmonary embolism 
11 822 M/B 28 25.3 138 8.5 7.0 ASCVD 
12 727 M/B 19 7.0 155 9.2 7.2 Trauma 
13 871 M/W 28 16.5 128 8.5 7.1 Trauma 
14 575 F/B 55 11.3 177 9.6 6.8 ASCVD 
15 700 M/W 42 26.1 160 8.7 7.0 ASCVD 
16 988 M/W 82 22.5 106 8.4 6.2 Trauma 
17 686 F/W 52 22.6 162 8.5 7.0 ASCVD 
18 634 M/W 52 16.2 168 8.5 7.0 ASCVD 
19 852 M/W 54 8.0 131 9.1 6.8 Cardiac tamponade 
20 987 F/W 65 21.5 107 9.1 6.8 ASCVD 
21 818 F/W 67 24.0 140 8.4 7.1 Anaphylactic reaction 
22 857 M/W 48 16.6 130 8.9 6.7 ASCVD 
23 739 M/W 40 15.8 155 8.4 6.9 ASCVD 
24 1047 M/W 43 13.8 98 9.0 6.6 ASCVD 
25 1086 M/W 51 24.2 92 8.1 6.8 ASCVD 
26 1092 F/B 40 16.6 91 8.0 6.8 Mitral Valve Prolapse 
27 10005 M/W 42 23.5 79 7.4 6.7 Trauma 
28 1336 M/W 65 18.4 56 8.0 6.8 Cardiac Tamponade 
29 1122 M/W 55 15.4 88 7.9 6.7 Cardiac Tamponade 
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30 1284 M/W 55 6.4 67 8.7 6.8 ASCVD 
31 1191 M/B 59 19.4 80 8.4 6.2 ASCVD 
32 970 M/W 42 25.9 109 7.2 6.4 ASCVD 
33 10003 M/W 49 21.2 80 8.4 6.5 Trauma 
34 1247 F/W 58 22.7 73 8.4 6.4 ASCVD 
35 1324 M/W 43 22.3 59 7.3 7 Aortic Dissection 
36 1099 F/W 24 9.1 91 8.6 6.5 Cardiomyopathy  
37 1307 M/B 32 4.8 62 7.6 6.7 ASCVD 
38 1391 F/W 51 7.8 48 7.1 6.6 ASCVD 
39 1282 F/W 39 24.5 67 7.5 6.8 ASCVD 
40 1159 M/W 51 16.7 85 7.6 6.5 ASCVD 
41 1326 M/W 58 16.4 59 8.0 6.7 ASCVD 
42 902 M/W 60 23.6 124 7.7 6.7 ASCVD 
  Mean 48.1 17.8 120.7 8.3 6.8  
  SD 13.3 5.9 43.6 0.6 0.2   
 
Subjects with Schizophrenia 
Pair Case DSM IV diagnosis Sex/  Race Age PMI












M/W 40 29.1 184 8.4 6.8 Accidental Asphyxiation 
GABRA1, 
GAT1 
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F/B 38 17.8 175 9.0 7.0 Myocardial hypertrophy 
GABRA1, 
GAT1 







M/W 58 18.9 169 7.4 6.8 Right MCA infarction 
GABRA1, 
GAT1 


























14 517 Disorganized schizophrenia; ADC F/W 48 3.7 186 9.3 6.7 
Intracerebral 
hemorrhage GABRA1 










M/W 83 16.0 170 8.7 7.3 Accidental asphyxiation GABRA1 
17 656 Schizoaffective disorder; ADC F/B 47 20.1 166 9.2 7.3 
Suicide by 






M/B 45 9.1 156 9.2 6.7 Upper GI bleeding GABRA1 
19 781 Schizoaffective disorder; ADR M/B 52 8.0 146 7.7 6.7 Peritonitis GABRA1 














M/W 47 15.3 116 8.2 6.2 ASCVD GABRA1 
23 933 Disorganized schizophrenia M/W 44 8.3 116 8.1 5.9 Myocarditis GABRA1 





25 10025 Disorganized schizophrenia; OAR  M/B 52 27.1 71 7.8 6.7 ASCVD No 
26 1178 Schizoaffective disorder F/B 37 18.9 83 8.4 6.1 
Pulmonary 
embolism No 
27 1256 Undifferentiated schizophrenia M/W 34 27.4 71 7.9 6.4 
Suicide by 
hanging No 
28 1173 Disorganized schizophrenia; ADR  M/W 62 22.9 83 7.7 6.4 ASCVD No 
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M/W 58 7.7 81 8.4 6.2 ASCVD No 
31 1263 Undifferentiated schizophrenia; ADR  M/W 62 22.7 70 8.5 7.1 
Accidental 
asphyxiation No 
























36 10023 Disorganized schizophrenia F/B 25 20.1 72 7.4 6.7 
Suicide by 
drowning No 
37 10024 Paranoid schizophrenia M/B 37 6.0 72 7.5 6.1 ASCVD No 










40 1296 Undifferentiated schizophrenia M/W 48 7.8 65 7.3 6.5 Pneumonia No 
41 1314 Undifferentiated schizophrenia M/W 50 11.0 62 7.2 6.2 ASCVD No 
42 1361 Schizoaffective disorder; ODC M/W 63 23.2 54 7.7 6.4 
Cardiomyopat
hy No 
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  Mean 47.0 18.1 121.0 8.2 6.6   
   SD 12.8 8.7 46.1 0.7 0.4    





1 533 Y N N 
2 537 N N N 
3 547 Y Y Y 
4 566 Y Y Y 
5 581 Y N Y 
6 587 Y N Y 
7 625 Y Y N 
8 622 N N N 
9 640 Y Y N 
10 665 Y Y N 
11 787 Y N N 
12 829 N N Y 
13 878 Y Y Y 
14 517 Y N N 
15 539 Y Y Y 
16 621 N N N 
17 656 Y N N 
18 722 Y N N 
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19 781 Y Y N 
20 802 Y N Y 
21 917 Y N N 
22 930 Y N Y 
23 933 Y Y Y 
24 1209 Y N N 
25 10025 N N N 
26 1178 Y N Y 
27 1256 Y N N 
28 1173 Y N N 
29 1105 Y N N 
30 1188 Y N N 
31 1263 Y Y N 
32 1222 Y Y N 
33 1088 Y Y N 
34 1240 Y N N 
35 10020 Y Y Y 
36 10023 Y N Y 
37 10024 N N N 
38 1189 Y Y Y 
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39 1211 Y Y N 
40 1296 Y Y N 
41 1314 Y Y N 
42 1361 Y N Y 
  36Y/6N 17Y/25N 15Y/27N 
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A.2 RHESUS MACAQUE MONKEYS USED IN THIS DISSERTATION                                        
(ALL FEMALE EXCEPT FOR SUBJECT 282) 















(0.25 to 1) 
193 0.25 Female NA - - 120 
 
194 0.25 Female NA - - 119 
 
199 0.25 Female 0.5 - - 106 
 
201 0.25 Female 0.4 - - 106 
 
285 0.25 Female 0.6 - - 23 
 
196 1 Female NA - - 115 
 
197 1 Female NA - - 114 
 
200 1 Female 0.6 - - 106 
 
209 1 Female 0.6 - - 97 
Childhood  
(3 to 9) 
192 3 Female 0.8 - - 120 
 
198 3 Female 0.8 - - 112 
 
203 3 Female 0.9 - - 103 
 
212 3 Female 1.1 - - 94 
 
234 3 Female 0.9 + - 70 
 
241 3 Female 1.0 + - 63 
 
245 3 Female 1.2 + - 55 
 
277 3 Female 1.0 + - 31 
 294 8 Female 1.8 - - 11 
 261 9 Female 1.6 - - 42 
 262 9 Female 1.8 - - 42 
 273 9 Female 2.0 + - 36 
 278 9 Female 1.6 - - 31 
Adolescence 
(15 to 37) 
240 15 Female 2.3 + - 63 
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264 15 Female 2.5 + - 42 
 
265 15 Female 2.4 + - 44 
 
275 15 Female 2.4 + + 33 
 255 16 Female 2.6 + - 44 
 
287 18 Female 2.4 - - 15 
 
286 19 Female 2.4 - - 15 
 
293 23 Female 3.2 - - 12 
 
297 30 Female 4.9 - - 7 
 
298 30 Female 4.2 - - 7 
 
280 32 Female 3.8 + - 27 
 
281 32 Female 3.7 + - 27 
 
291 32 Female 3.9 - - 13 
 
279 33 Female 4.5 + - 28 
 
295 35 Female 4.3 + + 10 
 
296 35 Female 4.4 + + 9 
 
292 37 Female 5.0 - - 12 
Adulthood 
(42 to 138) 
249 42 Female 6.2 + - 53 
 239 42 Female 5.5 + - 63 
 
289 45 Female 5.7 - - 15 
 
258 46 Female 6.3 + - 43 
 
267 46 Female 5.7 + + 40 
 
269 46 Female 4 + + 38 
 
288 47 Female 5 - - 15 
 
259 104 Female 6.4 + - 43 
 
282 108 Male 11.7 - - 26 
 
260 138 Female 9.5 - - 43 
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APPENDIX B 
COMPUTATIONAL ESTIMATES OF AGE EFFECTS ON GAD67 MRNA LEVELS 












Figure 22. Computational estimate of age effects on GAD67 mRNA levels prior to and after illness onset in 
the schizophrenia subjects 
Regression model is used for schizophrenia subjects to estimate the slopes of GAD67 mRNA expression changes 
before and after illness onset (solid line), where β0
s represents intercept (i.e. transcript level at birth), β1s and β2s 
represent the slopes of GAD67 mRNA levels decline before and after illness onset, respectively. Rejecting the 
hypothesis H0: β1s=β2s versus HA: β1s≠β2s implies that the effect of age for schizophrenia subjects is fit by a 
segmented line with differing slope before and after illness of onset. The slope of GAD67 mRNA expression 
decline over age for comparison subjects can also be obtained from a linear regression model (dashed line). 
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